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ABSTRACT OF THE DISSERTATION 
EPIGENETIC MECHANISMS REGULATING THE FUNCTIONAL EFFECTS OF 
CHRONIC ALCOHOL EXPOSURE OF HUMAN MONOCYTE-DERIVED DENDRITIC 
CELLS. 
by 
Tiyash Parira 
Florida International University, 2018 
Miami, Florida 
Professor Marisela Agudelo, Major Professor 
The effects of alcohol abuse are multi-dimensional since alcohol is widely known 
to affect both the innate and adaptive immune systems. Recently, epigenetics has come 
into focus and has been implicated in many diseases as well as substance abuse 
disorders. Therefore, research efforts of understanding the epigenetic mechanisms 
underlying substance abuse effects including alcohol abuse have become more 
predominant.  
In our laboratory, we have studied different epigenetic changes induced by 
alcohol exposure including regulation of histone deacetylases (HDACs), histone 
quantity, and histone modifications such as acetylation and deacetylation. We have 
observed differential effects of acute and chronic alcohol exposure in human monocyte-
derived dendritic cells (MDDCs) wherein our laboratory previously found that HDACs 
were modulated in MDDCs treated acutely with alcohol in vitro, and in MDDCs from 
alcohol users. Our previous work has also demonstrated that alcohol consumption 
affects the dendritic cell function by modulating inflammatory markers and cannabinoid 
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receptors such as CB2 and GPR55 through epigenetic modifications. For instance, 
chronic alcohol exposure upregulates histone (H) 4 acetylation at lysine 12 (H4k12ac) 
and acute alcohol effects on histone acetylation are associated with an increase in 
GPR55 expression.  
The hypothesis of the study is that chronic alcohol modulates human MDDC 
function through epigenetic mechanisms. Therefore, the primary objective of this 
research project is to elucidate novel pathways involving histone post-translational 
modifications due to chronic alcohol exposure in human dendritic cells.  
For this study, monocytes isolated from commercially available human buffy 
coats were differentiated into MDDCs, which were treated with chronic alcohol levels of 
0.1 % (100mg/dL) and 0.2 % (200mg/dL) for 5 days in the presence or absence of the 
histone acetyltransferase inhibitor NU9056 (50nM) or the GPR55 antagonist 
CID16020046 (5µM). Results showed that chronic alcohol levels upregulated H4K12ac 
in MDDCs and this was associated with a concomitant increase in GPR55 gene and 
protein expression. Further, NU9056 and CID16020046 were able to reduce alcohol-
induced inflammatory chemokine MCP-2 and reactive oxygen species production 
indicating that H4K12ac may be an inflammation and oxidative stress regulator.  
Additionally, NU9056 and CID16020046 could potentially reduce alcohol-induced 
inflammation and serve as potential therapeutic targets for alcohol use disorders. 
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CHAPTER 1. INTRODUCTION 
1. Introduction 
According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), 15.1 
million adults in the United States suffer from alcohol use disorders (AUDs) . The grave 
morbidities of AUDs range from an increased risk for certain cancers to death. One of the 
most severe yet under-studied mechanisms is the effect of alcohol on the human immune 
system. Several studies have revealed that alcohol abuse negatively affects the innate 
and adaptive immune systems, making them more vulnerable to infection (Szabo and 
Saha, 2015, Molina et al., 2010). Specifically, studies focused on the innate immune 
system have shown that, chronic alcohol abuse can cause skewed peripheral NK (natural 
killer) cell development and maturation (Zhang et al., 2017) along with severe intestinal 
permeabilization leading to cirrhosis (Keshavarzian et al., 1999b). Alcohol has also been 
shown to cause severe dysfunction in leukocyte recruitment during infections which can 
cause easily treatable infections to get severe (Zhang et al., 2002).  Furthermore, alcohol 
abuse can deeply alter the functionality of one of the primary antigen presenting cells of 
the innate immune system, known as dendritic cells, by altering their stimulatory ability 
(Szabo et al., 2004), or by modulating cytokine and chemokine secretion at the 
bronchoalveolar region in case of cigarette smokers (Burnham et al., 2013), in 
hepatocytes and kupfer cells in case of chronic alcohol intoxication (Dong et al., 2016) or 
in case of dendritic cells from alcohol user (Nair et al., 2015).  
Over recent years, alcohol exposure related studies have found molecular 
pathways like involvement in GABAergic and NMDA receptor pathways in the brain (Ron 
and Barak, 2016, Alfonso-Loeches and Guerri, 2011). Additionally, inflammation and 
3 
 
oxidative stress related pathways in the periphery (Louvet and Mathurin, 2015) have also 
shown to be profoundly associated with the effects of alcohol in the human brain and body. 
However, much still remains to be elucidated with regards to alcohol’s mechanisms of 
action in the human body, especially in the human immune system.  
One of the emerging fields of study in the substance abuse research area is 
epigenetics. Epigenetics is the combined study of histones, histone post-translational 
modifications, DNA methylations and non-coding RNA based mechanisms that 
collaborate to alter gene expression or genetics (Huang et al., 2014).  Epigenetic studies 
have paved the road to understanding several complex medical disorders and have 
introduced a new realm of epigenetic biomarkers and drug targets (Huang et al., 2014, 
Helin and Dhanak, 2013). The study of epigenetics has its own implications in alcohol 
research, and understanding the epigenetic mechanisms and pathways of alcohol has 
shown much potential and continues to remain a promising field of research (Jangra et 
al., 2016, Krishnan et al., 2014). 
Alcohol has also been associated with the modulation of cannabinoid receptors in the 
human body (Nair et al., 2015, Pava and Woodward, 2012, Kleczkowska et al., 2016, 
Vasiljevik et al., 2013, Chanda et al., 2013, Ortega-Alvaro et al., 2015, Al Mansouri et al., 
2014, Agudelo et al., 2013). Cannabinoid receptors (CB1, CB2) are endogenous receptors 
which were first studied in the context of endocannabinoids and CB1 was found to be 
present primarily in the brain (Matsuda et al., 1993) and CB2 primarily in the immune 
system (Munro et al., 1993, Felder and Glass, 1998). However, over the years, CB1 has 
been found in peripheral tissues like cardiovascular and reproductive systems while CB2 
has been found in the central nervous system and neurons (Svíženská et al., 2008). The 
association of alcohol with the endocannabinoid system has been studied at length along 
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with cannabinoid receptors being studied as potential therapeutic drug targets for Alcohol 
Use Disorders (AUDs) (Onaivi, 2008, Pava and Woodward, 2012). Currently, with the 
existence of novel cannabinoid receptors like GPR55 (Ryberg et al., 2007), which are also 
being referred to as “type 3” cannabinoid receptors (Yang et al., 2016), newer studies 
targeted towards finding the therapeutic potential of such novel cannabinoid receptors are 
on the rise (Shore and Reggio, 2015b, Morales and Jagerovic, 2016). Alcohol has recently 
also been shown to modulate GPR55 in the brain (Serrano et al., 2012) and in the 
periphery (Agudelo et al., 2013). Therefore, the question behind the advantages of the 
cannabinoid receptors especially novel GPCRs like GPR55, and their usefulness as drug 
targets for AUDs remains to be answered. 
1.1  Alcohol use disorder and its public health impact 
 
According to the National Institutes on Alcohol Abuse and Alcoholism (NIAAA) , 
AUD is a resulting effect of chronic problem drinking. Alcohol consumption can be 
classified as acute, chronic, binge drinking. Acute drinking refers to one episode of binge 
drinking causing acute effects of alcohol-like intoxication and chronic levels refer to more 
than one episode of moderate or binge drinking resulting in chronic effects of alcohol like 
dependence, chronic inflammation, and even cancer among other effects (Faden and 
Goldman, 2005). Car crashes due to driving under influence (DUI) can occur due to acute 
or chronic alcohol drinking. Another grave co-morbidity of alcohol consumption is that of 
fetal alcohol spectrum disorder which happens in children whose mothers were consuming 
alcohol during pregnancy (Riley et al., 2011). According to the 2015 National Survey on 
Drug Use and Health (NSDUH), 15.1 million adults ages 18 and older had an AUD. This 
includes 9.8 million men (8.4 percent of men in this age group) and 5.3 million women (4.2 
percent of women in this age group) (NSDUH, 2015) In 2010, alcohol misuse cost the 
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United States $249.0 billion towards this preventable cause of morbidity and death (Sacks 
et al., 2015). According to the World Health Organization in 2014, alcohol consumption 
lead to more than 200 diseases and injury-related health conditions including liver cirrhosis 
and cancer (Organization and Unit, 2014). According to a study, more than 10 percent of 
the children in the United States live with a parent who has alcohol drinking problems 
(NIAAA, 2012). When it comes to treatments for AUDs, most treatments are based on 
therapy to control addiction behavior to alcohol (Yoon and Petrakis, 2018). Similarly drugs 
like naltrexone, acamprosate and disulfiram help in dealing with addiction (Yoon and 
Petrakis, 2018). However, more specific and efficient pharmacological treatment plans 
towards AUDs need to be studied. In conclusion, AUD continues to remain a public health 
concern and more active and effective research needs to continue to contribute towards 
establishing cures or treatments for AUDs.  
1.2  Alcohol metabolism – an overview 
Before going into details about molecular mechanisms of alcohol, this section will 
provide a brief outline of how alcohol is metabolized in the human body. After alcohol 
ingestion, almost all of it that is absorbed is metabolized in the liver (Lieber, 1997). 
Elimination of alcohol depends on several factors like gender (Cole-Harding and Wilson, 
1987), age, race (Reed et al., 1976) or exercise patterns (Cederbaum, 2012) and diet 
(Ramchandani et al., 2001). In hepatic cells, alcohol can be metabolized by three different 
mechanisms. It can either be metabolized by alcohol dehydrogenase or ADH in the cytosol 
or it can undergo oxidation in the microsomes or it can be metabolized by catalase 
enzymes in peroxisomes (Caballería, 2003). All these mechanisms form acetaldehyde as 
one of the products which also happens to be the most toxic amongst all alcohol 
metabolites (Caballería, 2003). One of the main limitations of alcohol metabolism by ADH 
is the availability and hence capacity of ADH (Cederbaum, 2012). For example, availability 
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of ADH is more in the liver when alcohol is consumed after food intake than in fasting 
conditions (Cederbaum et al., 1977). Acetaldehyde is further metabolized to acetate in the 
mitochondria with the help of acetaldehyde dehydrogenase or ALDH which is ultimately 
released into the blood to be converted or oxidized further to simple molecules like carbon 
dioxide, water, and fatty acids (Caballería, 2003, Cederbaum, 2012).  For both of these 
reactions by ADH and ALDH, NAD+ is reduced to NADH + H+ which when it occurs during 
binge alcohol exposure conditions leads to altered NAD+/NADH ratio in the cells (Veech 
et al., 1972). This altered ratio especially in the mitochondria affects other reactions like 
mitochondrial oxidation as it affects the availability of NAD+/NADH which leads to ROS 
generation (Veech et al., 1972).  The highest amount of cytochrome P450 group enzymes 
is present in microsomes, amongst which, CYP2E1 has the highest affinity for 
metabolizing alcohol to acetaldehyde, this process eventually becomes responsible for 
producing the maximum amount of reactive oxygen species making it an important player 
in alcohol-related diseases with an oxidative stress component  (Cederbaum, 2012). 
1.3 Molecular mechanisms of action of alcohol in the human brain and periphery 
Alcohol’s mechanism of action is a topic that has attracted a lot of researchers and 
still continues to remain questionable. We have recently published a review paper (Parira 
et al., 2017d) that also discusses the same. Several researchers have incorporated 
different cellular and animal models to understand the mechanisms behind addiction 
behavior due to alcohol by studying brain cells and tissues in vitro or in vivo under acute 
and chronic alcohol conditions. When it comes to understanding the effect of alcohol in 
the brain, while acute alcohol exposure causes changes or temporary modifications for 
hours, chronic alcohol exposure causes an alteration in synapses and changes in overall 
circuitry (Most et al., 2014). Researchers have studied the effects of alcohol in the context 
of different neurotransmitter systems. An important target for alcohol studies is N-methyl-
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D-aspartate (NMDA) receptors that are mostly associated with the glutamatergic pathways 
involved in learning and memory (Morris, 2013, Wang and Peng, 2016). For instance, 
there is some evidence that alcohol utilizes NMDA receptors for its effects through protein 
kinase C (Li et al., 2005). In vitro, acute alcohol treatment on hippocampus reduces NMDA 
activity correlating to levels that result in intoxication in humans and is directly 
proportionate to levels of intoxication (Lovinger et al., 1989). Dopamine and dopamine 
receptors have also been demonstrated to be affected by alcohol as rats that are bred to 
prefer alcohol produce more dopamine than wild-type rats in a study using an animal 
model of alcohol self-administration (Weiss et al., 1993). In a rat model of chronic 
intermittent ethanol exposure, ethanol was found to almost completely damage the 
signaling from D2/D4 and it also disrupted the cognitive function of the medial prefrontal 
cortex (Trantham-Davidson et al., 2014). Ras-specific guanine-nucleotide releasing factor 
2 (RASGRF2) was found to control dopaminergic downregulation in the brain of 
RASGRF2 knockout mice after sub-chronic alcohol treatment (Easton et al., 2014). 
Finally, the  Gamma-aminobutyric acid or GABA receptor has also been deeply associated 
towards the functionality of alcohol in brain (Maccioni and Colombo, 2009). GABA A 
receptors in dorsal raphe nucleus were shown to be responsible for alcohol-induced 
aggression with GABA A receptor agonist Muscimol further escalating this aggression in 
presence of alcohol but having no effect in absence of it (Takahashi et al., 2010). 
Interestingly a review paper discussed the role of G protein-coupled receptors or GPCRs 
like cannabinoid receptor 1 or CB1 and GABA B receptor in modulating or regulating 
alcohol-induced GABA release (Kelm et al., 2011).  
On the other hand, several groups have also studied alcohol’s debilitating effect in 
the human periphery and peripheral organs like the liver and immune system as reviewed 
by Molina et al. (Molina et al., 2010).  Alcoholic liver injury or liver cirrhosis involves 
8 
 
interaction between many pathways and cell types. Under the effect of alcohol, liver 
macrophages or Kupfer cells are sensitized and become vulnerable to endotoxin or 
bacterial lipopolysaccharide (LPS) which is considered as a hallmark of alcoholic liver 
disease (Mandrekar and Szabo, 2009).  Toll-like receptor 4 (TLR4) on macrophages and 
other cell types recognizes LPS in the liver which causes downstream activation of several 
signaling pathways like the MAP kinases ultimately leading to activation of transcription 
factors like NFkB (Mandrekar and Szabo, 2009).  These pathways lead to inflammation 
and generation of reactive oxygen species (Cederbaum et al., 2009). Leaky gut due to 
alcohol abuse has been shown to be a possible causative factor for alcohol-induced liver 
injury (Keshavarzian et al., 1999a). When it comes to the innate immune system, alcohol 
severely affects monocytes, macrophages, dendritic cells and natural killer cells amongst 
others (Molina et al., 2010). Several studies have shown that alcohol adversely affects 
different functional properties of monocytes by reducing their phagocytic ability and cell-
cell adherence (Morland et al., 1988). Alcohol has also been shown to increase expression 
of certain receptors like CCR5 on macrophages which makes them more susceptible to 
HIV and SIV infections (Marcondes et al., 2008, Bagby et al., 2006, Bagby et al., 2003). 
Alcohol abuse also negatively affects all components of the innate immune system 
specifically the inflammatory response depends on whether the exposure was acute or 
chronic.  Studies on human monocytes and rodent macrophages have shown that acute 
alcohol exposure causes a decrease in TLR responses which blunts the TNFa response, 
however, this effect wears off with repeated or long-term alcohol exposure and long-term 
alcohol exposure leads to loss of TLR4 tolerance (Bala et al., 2012) (Mandrekar et al., 
2009a). In the context of DCs, alcohol has been shown to negatively affect exogenous 
antigen presentation by DCs by reducing the amount of peptide-MHCII complexes that 
are present on DCs, it also altered co-stimulatory molecules expression on the DC’s (Eken 
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et al., 2011). Chronic ethanol exposure was also found to damage migratory capacity of 
cutaneous DCs modulating skin immunity (Parlet and Schlueter, 2013). Another study 
which looked into the mechanism by which DC function of co-stimulation was affected by 
chronic alcohol exposure, DCs derived from mice post chronic alcohol feeding were found 
to express lower amounts of costimulatory molecules like CD40, CD80 or CD86 and 
produce less cytokines IL12-p40, TNFalpha and IFNalpha compared to mice that were 
water fed (Fan et al., 2011).   
When it comes to the adaptive immune system, alcohol has been shown to 
adversely affect it causing immune dysregulation. The result of such immunodeficiency 
leads to increased vulnerability to bacterial pneumonia, tuberculosis, and other kinds of 
infectious diseases (T., 1998). Chronic alcohol exposure negatively affects almost all 
modules of the adaptive immune system (Pasala et al., 2015). Peripheral DC cells from 
alcoholics without liver disease patients were shown to have significantly reduced HLA-
DR expression along with an increase in inflammatory cytokines secretion like IL-6, IL-12 
and TNFα (Laso et al., 2007). Several studies performed in both humans and animal 
models of chronic alcohol drinking showed it reduced the quantity of T cells, alters the 
balance between the different subtypes, affects their activation and functioning and in the 
end also promotes apoptosis (Pasala et al., 2015).   
1.4 Epigenetic mechanisms of alcohol action 
Epigenetics, which encompasses three broad topics of DNA methylation, histone 
modifications, and micro RNA mediated mechanisms of gene regulation, has been in the 
spotlight of research in trying to understand the mechanism of action of different 
substances (Huang et al., 2014). Similarly, in the case of alcohol, many studies have 
looked at the epigenetic effects of alcohol in order to understand its mechanism of action.  
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Our recently published review paper discusses such epigenetic mechanisms in detail 
(Parira et al., 2017d). Especially in the case of histone modifications which was the focus 
of this dissertation. Previous studies on alcohol and histone modifications, originated with 
rat hepatocytes being treated with alcohol in a dose and time-dependent manner and 
reported that acetylation at the 9th lysine residue on histone H3 was upregulated after 24 
hours of alcohol exposure (Park et al., 2003). Other studies have also shown differential 
effects of alcohol in the liver such as increased acetylation at H3K9, increase in 
phosphorylation at serine 10 and 28 among others (Park et al., 2005, Lee and Shukla, 
2007). Apart from acetylation, phosphorylation at H3 ser 10 and 28 and 
phosphoacetylation at K9S10 have also been shown to be associated with expression of 
early response genes like c-fos, c-jun and MAP kinase phosphatase-1 in the liver of rat 
models of acute alcohol exposure (James et al., 2012). Studies of acute alcohol exposure 
in the brain showed an increase in histone H3 and H4 acetylation in rat amygdala (Pandey 
et al., 2008), while chronic intermittent alcohol exposure increased H3K9ac and H4K12ac 
in the frontal cortex region (Pascual et al., 2009). In a study using ethanol-conditioned 
rats, reduced alcohol consumption and preference was observed when the animals were 
injected with HDAC inhibitor Valproic acid (Al Ameri et al., 2014). Nonetheless, most of 
the studies described above focused on the brain or liver, leaving the body’s immune 
system especially specific and vulnerable cell populations like dendritic cells understudied. 
More on this topic will be discussed in Chapter 3 section 3.1, with emphasis on the studies 
carried out previously by us.   
Apart from histone modifications, the role of alcohol towards modulating DNA 
methylation status had been studied prior. Acetaldehyde, a metabolite of alcohol had been 
shown to modulate DNA methylation by blocking DNA methyltransferases (Chen et al., 
2011). In a model of alcohol dependency, post dependent rats showed increased drinking 
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associated with increased DNA methylation correspondingly decreasing neurotransmitter-
related genes in the medial prefrontal cortex (Barbier et al., 2015).  A study found binge-
like alcohol to block DNA methylation in neural stem cells altering their functionality and 
adversely affecting differentiation by distressing critical genes like   insulin-like growth 
factor 1 (Igf1), in cases of eye development, lens intrinsic membrane protein 2 (Lim 2); the 
epigenetic mark Smarca2 (SWI/SNF related, matrix associated, actin dependent regulator 
of chromatin, subfamily a, member 2); and developmental disorder DiGeorge syndrome 
critical region gene 2 (Dgcr2)(Zhou et al., 2011). In a study of FASD, children born with 
FASD were found to have unique DNA methylation defects accompanied by changes in 
genes related to protocadherins, glutamatergic synapses, and hippo signaling (Laufer et 
al., 2015). Tissue plasminogen activator or tPA is one of the primary proteins in astrocytes 
responsible for neuronal plasticity and found to be increased by ethanol which was similar 
to an effect under DNMT inhibitor (Zhang et al., 2014b). Further, DNMT 3A but not DNMT 
1 was found to be reduced in astrocytes after alcohol exposure (Zhang et al., 2014b). 
These studies further revealed tPA as a regulatory protein in the ethanol-DNA methylation 
axis.  
Alcohol has also widely been shown to modulate the micro RNA landscape in 
humans. Several studies have shown the role of alcohol in modulating different micro 
RNAs as reviewed by Szabo and Bala (Szabo and Bala, 2013). Acute binge alcohol 
drinking was found to induce miR-27a expression in human monocytes which in turn 
modulated expression of ERK signaling that in turn affected monocyte activation and 
polarization (Saha et al., 2015). In another study miR-339-5p was found to prevent alcohol 
induced brain inflammation via NFB signaling pathway in microglial cells isolated from 
alcohol exposed brain tissue (Zhang et al., 2014c).  Some specific micro-RNAs are also 
emerging to be markers for certain liver diseases including alcoholic liver diseases like 
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micro RNA 122 (Zhang et al., 2010). Additionally, some micro RNA based mechanisms of 
alcohol have also been associated with the GABA receptor hence deepening the 
understanding of epigenetic effects of alcohol (Sathyan et al., 2007).  
1.5 The endocannabinoid system 
The endocannabinergic system consists of endocannabinoids (anandamide and 
2-arachidonoylglycerol), cannabinoid receptors (traditional CB1 and CB2 and novel ones 
like GPR55), enzymatic degradation systems, (through the fatty acid amide hydrolase or 
FAAH enzyme for anandamide and the monoacylglycerol lipase enzyme for 2-
arachidonoylglycerol) and cannabinoid transport reuptake system (Le Foll and Tyndale, 
2015). CB1 receptors which are primarily present in the brain (Devane et al., 1988), while 
CB2 receptor have been shown to be present more in the periphery (Munro et al., 1993). 
However, many studies thereafter have reported CB1 receptors to be present in periphery 
(Tam et al., 2010) and CB2 receptors have been discovered in the brain (Onaivi et al., 
2006), their levels however are lower in these locations. (Mechoulam and Parker, 2013). 
In case of cannabinoid receptors as therapeutic targets, more focus has been put on CB2 
receptors since compounds modulating CB2 eliminate the brain related effects 
(Dhopeshwarkar and Mackie, 2014) . A recent review discusses how CB2 receptor 
agonists have been shown to be immunosuppressive and have an immense future in 
therapeutic applications for autoimmune diseases and graft rejection (Eisenstein and 
Meissler, 2015). GPR55 which has been referred to as type 3 or novel cannabinoid 
receptor (Yang et al., 2016) has also been discussed to show their possible therapeutic 
potential (Shore and Reggio, 2015b). While GPR55 has been reported to couple to Gα13, 
Gα12, or Gαq  proteins with activation of PLC, RhoA, ROCK, ERK, p38 mitogen-activated 
protein kinase, and Ca2+ release that can induce downstream transcription factors such 
as Nuclear factor of activated T-cells (NFAT), nuclear factor kappa-light-chain-enhancer 
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of activated B cells (NF-κB), CAMP Responsive Element Binding Protein (CREB), and 
Activating Transcription Factor 2 (ATF2) (Shore and Reggio, 2015a), CB1 and CB2 show 
biased signaling in the sense that relative activation of Gαi and Gαo is dependent on the 
agonist leading to either activation or inhibition adenylyl cyclase with further activation of 
MAP kinases (Ibsen et al., 2017).  
1.6 Alcohol and the endocannabinoid system 
Alcohol’s association with cannabinoid receptors and the cannabinergic pathway 
has been and is still being studied quite extensively. Several studies in rodent models 
have shown cannabinoid agonists and antagonists to have an effect on alcohol self-
administration. In a study in mice model with a two-bottle choice paradigm, CB2 agonist β-
caryophyllene showed a dose-dependent decrease in alcohol preference and drinking (Al 
Mansouri et al., 2014). Chronic ethanol exposure has been shown to down-regulate CB1 
receptor function (Basavarajappa and Hungund, 2002). In another study, when adolescent 
rats were exposed to alcohol were compared to controls, CB1 receptor and nuclear PPARα 
were found to be lower in spleens; From alcohol-fed animals however, CB2 was higher 
showing that exposure to alcohol can bring about significant differences in cannabinergic 
receptor expression (Pavon et al., 2016).  In yet another study in mice with ATG5 
(autophagy related gene) knockout model, researchers showed that CB2 receptor 
activation in liver macrophages protects them from steatosis in an autophagy-dependent 
pathway (Denaes et al., 2016). In a recent interesting study, the researchers found that 
acute alcohol exposure in humans increased CB1 in the cerebrum and this effect was 
reversed in chronic alcohol exposure that is again maintained for a time period of at least 
a month (Ceccarini et al., 2014). Recently interaction between CB2 and social environment 
was shown to modulate chronic alcohol consumption (Pradier et al., 2015). In this study, 
a mice model was used where CB2 knockout mice were compared to wildtype with 
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different social environment groups of single or grouped housing and forced or two bottle 
choice paradigms for alcohol drinking (Pradier et al., 2015). Interestingly, the study 
showed CB2 knockout mice were drinking more when housed in groups and given an 
intermittent forced drinking paradigm (Pradier et al., 2015). Further studies especially the 
ones previously published by us will be described later in Chapter 4, section 4.1. We have 
also published a review paper discussing the alcohol cannabinergic pathway association 
and the studies showing epigenetic basis of these interactions (Parira et al., 2017d).  
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CHAPTER 2: HYPOTHESIS AND RESEARCH QUESTIONS 
2.1 Objective of the Study  
The goal of this study was to understand the epigenetic effects of chronic alcohol 
treatments in human MDDCs and find out the epigenetic mechanisms behind alcohol’s 
modulation of cannabinoid receptors.  
2.2 Hypothesis:  
The hypothesis of the study is that chronic alcohol treatment modulates human MDDC 
function through epigenetic mechanisms.  
2.3 Research questions:  
 
The study was divided into three questions:  
a) How does chronic alcohol treatment modulate epigenetic modifications in 
human MDDCs? 
b) Do these epigenetic changes under chronic alcohol treatment modulate human 
MDDC function? 
c) What are the mechanisms that underlie the functional effects exerted by 
chronic alcohol exposure of human MDDCs? 
The following sections will discuss in details each question individually by giving a short 
introduction to each, detailing the methods and results and then discussing the results. 
The dissertation will finally conclude with a common conclusion and future directions 
section.   
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CHAPTER 3: RESEARCH QUESTION 1: How does chronic alcohol treatment 
modulate epigenetic modifications in human MDDCs? 
 
1.1 Introduction 
 
In our laboratory, we have previously published about the role of histone 
deacetylases (HDACs) in human monocyte-derived dendritic cells (MDDCs) and neuronal 
cells under acute alcohol exposure and MDDCs from alcohol users. In neuronal cells, SK-
N-MC, acute treatment with alcohol showed increased expression of class I HDACs and 
a corresponding increase in ROS production (Agudelo et al., 2011, Agudelo et al., 2012). 
We have recently shown that in in vitro studies acute alcohol exposure is able to modulate 
class I HDACs, specifically upregulating gene expression of HDAC 1,2,3 and 8 (Agudelo 
et al., 2016). Further, in MDDCs derived from alcohol users, there was also a significant 
increase in gene expression of all class I HDACs and protein expression of HDAC 2 and 
8 (Agudelo et al., 2016). Additionally, there was an increase in total HDAC activity in 
alcohol users compared to non-users while gene expression array and in silico analysis 
for the class I HDACs also showed modulation of oxidative stress-related genes (Agudelo 
et al., 2016).  
Additionally, preliminary data for HDAC activity and expression of HDACs either did not 
show significant differences or showed lower levels compared to control for MDDCs 
treated chronically with alcohol, and since a decrease in HDAC activity or lack of activity 
might result in an increased in acetylation, for this project we decided to focus on looking 
deeper into histone post-translational modifications focused at acetylations in MDDCs due 
to chronic alcohol exposure. Histone post-translational modifications being more intrinsic 
in the epigenetic pathways and closer to modulating gene expression were selected in 
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order to elucidate alcohol-induced epigenetic and cannabinergic association. All data 
under this section have been published recently (Parira et al., 2017b). 
3.2 Methods 
3.2.1 MDDC Isolation – Human MDDCs were isolated from commercially available buffy 
coat from community blood bank (One Blood, FL). In brief, blood was diluted with PBS 
and white blood cell layer was separated using density gradient separation. White blood 
cell layer was pipetted out, washed with PBS and residual red blood cells were lysed using 
Ammonium-Chloride-Potassium (ACK) lysing buffer (Quality biologicals). Resulting 
peripheral blood mononuclear cells (PBMCs) were plated with RPMI media (Gibco) and 
after 2 hours floating cells were discarded while adherent monocytes were washed and 
cultured for 5 to 7 days with cytokines 100 U/mL IL-4 and 100 U/mL GM-CSF (R & D 
systems) to differentiate into MDDCs.  
3.2.2 Chronic alcohol treatment and Measurement of alcohol concentration – 
Initially, to optimize alcohol concentrations and to confirm daily dose of alcohol, a separate 
experiment was performed to check daily alcohol concentrations. Post differentiation, 
MDDCs were treated with alcohol (Ethanol or EtOH) 0.2% (200 g/dL or ~40mM) for 5 
days. Similar alcohol concentration was used in previous studies (Liang et al., 2014b). 
Alcohol-treated cells were kept in a separate incubator humidified with alcohol and the 
treatment was replenished in full every day. As alcohol is known to evaporate up to 90% 
after 24 Hours in neuroblastoma x glioma cells (Rodriguez et al., 1992). Our method of 
chronic alcohol treatment has been validated previously in monocytes where replenishing 
alcohol every day and keeping cells in alcohol-humidified incubator maintained 
concentration at 25mM±4.5 over a 7 day period (Mandrekar et al., 2009b). Further this 
technique of treatment has been described by the same group previously (Szabo and 
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Mandrekar, 2008). Alcohol concentration within the culture media was checked starting at 
48 hours then every 24 hours after that using a kit (Abnova) that measures color of product 
chromate converted from dichromate, a reaction that utilizes ethanol/alcohol, pre 
replenishment and 2 hours post replenishment with alcohol.  
3.2.3 Histone extraction and analysis of histone quantity and modifications ELISA 
– total histones were extracted using a total histone extraction kit (Epigentek) and total H3 
and H4 were quantified using H3 and H4 quantification kit using an ELISA based method 
of quantification of histones. H3 and H4 modifications were quantified using H3 
modification multiplex array (EpiQuik Histone H3 Modification Multiplex Assay Kit, 
Epigentek) and H4 modification multiplex array (EpiQuik Histone H4 Modification Multiplex 
Assay Kit, Epigentek) kits. In brief, equal amounts of protein were added for different 
samples in every experiment; however, overall protein concentration range from 100 to 
200 ng. H3 modifications were calculated according to manufacturer’s instructions which 
also accounts for protein amounts and the final values for each modification were 
presented as a percentage over untreated control. H4K12ac was also measured in histone 
extracts using H4K12ac quantification kit (Epigentek).  
3.2.4 H4K12ac western blot and Mass spectrometry analysis - Western blotting was 
carried out with 2 µg of total histone extracts from control cells and alcohol treated cells. 
They were electrophoresed on a 4–20% polyacrylamide gel (BIORAD) and labelled with 
primary antibody rabbit anti-human H4K12ac (EMD Millipore) (1:2000) and Horseradish 
peroxidase (HRP) labelled secondary antibody, anti-rabbit IgG (1:2000) (EMD 
MILLIPORE). Loading was controlled by normalizing H4k12ac blot intensities to histone 
H4 by labelling H4 with anti-human H4 (1:10,000) (Thermo Scientific™) and HRP labelled 
secondary anti-mouse IgG (1:10,000). Films were analyzed using Image J software.  
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Quantification of H4 acetylation levels in controls and alcohol treated samples was 
validated using MALDI-FT-ICR-MS in collaboration with mass spectrometry facility at the 
Department of Chemistry and Biochemistry. In brief, all the sample preparation was 
performed in our lab including histone extraction, histone quantification, and separation 
by SDS-PAGE followed by coomasie blue staining of gel. H4 bands were isolated from 
the gel  at the Mass Spectrometry facility for paid service of the H4 purification and analysis 
The procedure is available in details in published manuscript (Parira et al., 2017b).  
3.2.5 NU9056 treatment and single cell imaging flow cytometry -  Post differentiation, 
MDDCs were pre-treated with 50nM NU9056 for 1- 2 hours with replenishing treatment 
every 48 Hours along with media change (concentration selected based on viability 
studies, data available in manuscript (Parira et al., 2017b)). Cells that receive alcohol 
treatment were treated with 0.2% EtOH for 5 days. Post chronic alcohol treatment, cells 
were harvested and stained with fixable viability dye eFLUOR450 (eBioscience) to gate 
on viable cells only. Further, they were intra-nuclearly stained with a primary anti-H4K12ac 
antibody (EMD Millipore) and secondary anti-rabbit FITC labeled antibody (EMD Millipore) 
to visualize the localization and expression of H4K12ac labeled cells. Post-staining, cells 
were acquired by Amnis FlowSight, 10,000 live single cell images were acquired and data 
were analyzed through Ideas analysis software. 
3.2.6 Statistical Analysis - Data are expressed as mean ± standard error of mean (Xu et 
al.). Experiments were performed at least three times or otherwise indicated in the figure 
legends. Statistical analysis like student’s t-test and/or 1-way or 2-way ANOVA were done 
using either Microsoft Excel or GraphPad Prism software. For more than one treatment 
groups, post-hoc analysis like Tukey’s multiple comparisons test was also carried out to 
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test for significance. Values of the same have been expressed as F (DFn, DFd). P values 
were considered significant when they were ≤ 0.05.   
3.3 Results 
3.3.1 Chronic alcohol treatment regime maintains 0.2% alcohol concentration in 
human MDDCs. Post differentiation, MDDCs were harvested and treated with 0.2% EtOH 
and kept in an incubator humidified with same concentration of ethanol. EtOH 
concentration was assayed in the cell culture media on days 2, 3, 4 and 5 before and 2 
hours after replenishment. On measurement of alcohol concentration before 
replenishment, we saw almost 90% evaporation every 24 hours (data not shown). Similar 
evaporation rates have also been observed previously (Rodriguez et al., 1992, Hurley et 
al., 1987). As shown in Figure1, after replenishing the EtOH levels come back up close to 
0.2%. Hence daily replenishing of EtOH and incubating cells in EtOH incubator help 
maintain desired EtOH concentration in cells.  
3.3.2 Chronic alcohol treatment significantly increases histone H3 and H4 quantity 
in human MDDCs. Post chronic alcohol treatment, total histones were extracted from 
EtOH treated and untreated or control MDDCs. Isolated histones were analyzed for 
quantity of total histone H3 and H4 using ELISA based technique. As shown in figure 2, 
total H3 was significantly upregulated after 0.1% EtOH (111.6 ± 4.858, p = 0.033) and 
0.2% EtOH (138.1 ± 15.18, p = 0.027) while total H4 was significantly upregulated only at 
0.2% EtOH (214.5 ± 33.02, p = 0.0017) when compared to untreated control. 0.1% EtOH 
treated MDDCs only increased H3 significantly but not H4 compared to untreated MDDCs. 
For this reason, for the following modification array studies, H3 modification array was 
carried out for both 0.1% and 0.2% EtOH treated MDDCs while H4 modification array was 
carried out for only 0.2% EtOH treated MDDCs (Parira et al., 2017a). 
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3.3.3 Chronic alcohol treatment significantly decreases most histone H3 and H4 
post-translational modifications but significantly increases acetylation at 12th 
lysine on H4 (H4K12ac). Post chronic alcohol treatment, total histones were extracted 
from EtOH treated and untreated or control MDDCs. Isolated histones were analyzed for 
quantity of 21 H3 post-translational modifications and 10 H4 post-translational 
modifications using ELISA based modification arrays. Results of H3 modifications as 
shown in figure 3, show a significant downregulation compared to untreated MDDCs. 
H3K4me1 (82.78% ± 2.95, p = 0.004), H3K4me3 (87.25% ± 3.67, p = 0.025), H3K9me3 
(85.97% ± 5.17, p = 0.053), H3K27me2 (83.54% ± 6.30, p = 0.059), H3K36me3 
(78.63% ± 7.17, p = 0.041) and H3K18ac (83.62% ± 3.80, p = 0.013) were expressed at 
lower levels in comparison to untreated MDDCs. However, treatment with 0.1% EtOH did 
not significantly modulate H3 modification sites. While most H4 modifications show lower 
levels compared to untreated MDDCs such as H4K5ac (15.44% ± 28.31, p = 0.011), 
H4K8ac (33.69% ± 12.89, p = 0.0002), H4K20m2 (53.63% ± 10.55, p = 0.0009), H4K20m3 
(59.63% ± 10.55, p = 0.019), H4R3m2 (33.45% ± 10.27, p = 0.0003) and H4ser1P 
(49.36% ± 19.86, p = 0.025) in comparison to untreated MDDCs. Surprisingly, the only H4 
modification that show significantly higher levels compared to untreated control was 
H4K12ac (401.64% ± 123.40, p = 0.031). Based on these data, the following experiments 
were carried out to validate the alcohol-induced increase of H4K12ac in treated MDDCs 
compared to untreated control (Parira et al., 2017a). 
3.3.4 Chronic alcohol treatment induction of H4K12ac was further validated by 
western blot and mass spectrometry analysis (samples for mass spectrometry was 
acquired in our lab followed by mass spectrometry analysis carried out by FIU mass 
spectrometry facility). Post chronic alcohol treatment, total histones were extracted from 
EtOH treated and untreated or control MDDCs. Western blot experiments show MDDCs 
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treated chronically with 0.2% EtOH exhibited a significantly higher expression of H4K12ac 
(367.3 % ± 132.9, p = 0.05) in comparison to control or untreated MDDCs (100% ± 15.05). 
H4K12ac was normalized to total H4 as carried out in previous publications (Gaikwad et 
al., 2010, Esse et al., 2013). As shown in Fig. 4, the control and the 0.2% EtOH-treated 
MDDCs have K16 acetylated as indicated by the m/z 530.3045 and peptide 5-18 signal 
with higher relative abundances on the acetylated peptide in the treated MDDCs 
compared to an acetylated peptide in the control MDDCs (1.12 + /− 0.16 times) (panel d). 
Furthermore, a peptide signal was detected containing acetylation at K12 and K16 at m/z 
927.5365 peptide 10-18 (panel d) for the control and treated MDDCs, respectively, with 
higher relative abundances in the treated compared to the control MDDCs (1.73 + /− 0.12 
times) (panel d). A peptide signal was detected at m/z 1396.8026 peptide 14-18 (panel d) 
for the control and treated MDDCs corresponding to the acetylation of K5, K12, and K16; 
in this case, a higher relative abundance was also observed for the treated MDDCs 
compared to the control MDDCs (1.39 + /− 0.09 times) (panel d). These observations 
suggest higher levels of acetylation in MDDCs treated chronically with 0.2% EtOH 
compared to the untreated MDDCs. This study further confirms the upregulation of 
H4K12ac under chronic alcohol treatment (Parira et al., 2017a). 
3.3.5 Chronic treatment with histone acetyltransferase inhibitor NU9056 (50nM) 
significantly blocks alcohol-induced upregulation in H4K12ac. In order to further 
understand the role of H4K12ac, blocking of alcohol-induced H4K12ac was needed. For 
this purpose, according to literature, amongst other histone acetyltransferases, TIP60 was 
found to be most responsible for acetylation of H4K12 (Altaf et al., 2010, Wee et al., 2014). 
Further, a novel TIP60 inhibitor, NU9056 was being investigated for its effects and role in 
human neuronal cells (Tan et al., 2016a) . Based on the literature, NU9056 was selected 
and viability assay like trypan blue and XTT assay was carried out to select 50nM as an 
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optimum concentration for treatment in human MDDCs (data available in publication 
Parira et al, 2017c). Post differentiation, MDDCs were pre-treated with 50nM NU9056 for 
2 hours and then cells receiving alcohol treatment were treated with 0.2% EtOH for five 
days. Post-treatment, either cells were immune-labeled with fluorescent H4K12ac through 
intra-nuclear labeling or histone extracts were prepared for H4K12ac quantification using 
an ELISA based kit. The results have been shown in figure 5. As measured by ELISA 
shown in panel a, chronic exposure of MDDCs with 50 nM NU9056 (69.35 ± 15.96) 
reduces H4K12ac lower than basal levels compared to control (100 ± 22.65) while 0.2% 
EtOH treatment (138.2 ± 18.09, p = 0.05) significantly increases H4K12ac compared to 
control. Also, when the cells were co-treated with 0.2% EtOH and NU9056 (50 nM) 
(56.27 ± 31, p = 0.04), there was a significant reduction on H4K12ac compared to 0.2% 
EtOH-treated cells, confirming the ability of NU9056 to inhibit the effects of EtOH on 
H4K12ac. To further validate the ability of NU9056 to inhibit the effect of EtOH on 
H4K12ac, intra-nuclear staining to detect H4K12ac followed by single-cell imaging flow 
cytometry was carried out. Figure 5, panel b shows a representative colored histogram 
overlay of the intensity of channel 2 (H4K12ac-FITC). For isotype control (yellow), 
secondary antibody only (orange), control (red), NU9056 50 nM (pink), 0.2% EtOH (blue) 
and combination of 0.2% EtOH and NU9056 50 nM (green) treated MDDCs. The 
histogram overlay represents the shift in intensity of H4K12ac positive cells showing a 
decrease or leftward shift for NU9056 (50 nM), increase or rightward shift for 0.2% EtOH 
compared to control and a decrease again for the combination of 0.2% EtOH and NU9056 
(50 nM) in comparison to 0.2% EtOH-treated MDDCs. Panel d shows NU9056 (50 nM) 
(62.78% ± 3.53, p = 0.004) significantly reduced the percentage of H4K12ac positive cells 
compared to control (74.93% ± 1.73) while 0.2% EtOH increased the percentage of 
H4K12ac positive cells (82.95% ± 0.84, p = 0.0008) compared to control. When the cells 
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were treated with a combination of 0.2% EtOH and NU9056 (50 nM), there was a 
significant reduction on H4K12ac positive cells (68.21% ± 2.57, p = 0.0005) compared to 
cells treated with 0.2% EtOH alone. Panel c shows the mean fluorescent intensity (MFI) 
of H4K12ac-FITC positive cells. MDDCs treated with NU9056 50 nM (154451 ± 25304) 
shows reduced MFI compared to untreated MDDCs (172842 ± 28155). MDDCs 
chronically treated with 0.2% EtOH (203686 ± 41517) show increased MFI compared to 
control while MDDCs treated with 0.2% EtOH and NU9056 50 nM (133163 ± 23359, 
p = 0.0002) show significantly reduced MFI compared to 0.2% EtOH treated MDDCs. The 
results from panel d confirm that NU9056 50 nM in combination with 0.2% EtOH reduce 
alcohol-induced H4K12ac expression in MDDCs. Representative single cell images are 
shown in panel e. To confirm the nuclear co-localization of H4K12ac, treated or untreated 
MDDCs were labeled with H4K12ac using intra-nuclear staining protocol and followed by 
staining with 4′,6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI). Images were 
acquired, and panel f shows representative single cell images with the last channel 
showing an overlay of bright field, FITC and DAPI, confirming the nuclear co-localization 
of H4K12ac (Parira et al., 2017a). 
3.4 Discussion 
Epigenetics is a newly emerging field that is slowly gaining importance in 
understanding mechanisms of how various compounds or substances and even 
conditions and diseases function (Mann, 2014, Qureshi and Mehler, 2013, Stylianou, 
2013, Cao et al., 2014). In this study, we attempted to understand the epigenetics of 
chronic alcohol treatments in modulating functionality of human MDDCs. We first 
measured total histone quantity (histone H3 and H4) to understand if chronic alcohol 
treatments had any effect on overall histone levels. Our results showed chronic treatment 
with 0.2% EtOH significantly increased total histone H3 and H4 quantity in MDDCs 
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compared to untreated MDDCs (Figure 2). These results are consistent with other findings 
since histone quantity has been previously measured and found to be modulated due to 
deletion of High Mobility Group Box 1 protein (HMGB1) in mouse embryo fibroblasts and 
due to differentiation of mouse embryonic stem cells (Celona et al., 2011, Karnavas et al., 
2014b). As discussed in our recently published paper (Parira et al., 2017a), Celona et al., 
have shown that histone content is reduced in the cells which makes the chromatin more 
accessible and open to transcription (Celona et al., 2011). Another group has shown that 
histone quantity is increased in embryonic stem cells that are differentiating and which is 
also a symbol of pluripotency (Karnavas et al., 2014a). In our study, we observed an 
increase in histone content which may correlate with the MDDC differentiation stage and 
maturation effects induced by chronic exposure to EtOH (Parira et al., 2017a).  
Having seen increased H3 and H4 quantity, we assessed H3 and H4 post-
translational modification status in MDDCs post chronic alcohol treatment. Out of 21 
different H3 modifications that were quantified, most H3 modifications that showed 
significant differences were downregulated (Figure 3). A total of 10 different H4 
modifications were quantified and similarly most H4 modifications showed downregulation 
except acetylation at H4K12 or H4K12ac. We further confirmed our finding using western 
blot and mass spectrometry (collaboration with the MS facility at FIU). As discussed in our 
publication (Parira et al., 2017a) previous literature also shows an increase in H4K12ac in 
adolescent rats due to chronic intermittent alcohol exposure which is further correlated 
with increased oxidative stress (Pascual et al., 2009). In another report, in a transgenic 
model of Alzheimer’s disease, H4K12ac was found to be increased and correlated with an 
increase in inflammatory cytokines like MIP-2 and TNFα (Plagg et al., 2015). Additionally, 
in a study with pancreatic cancer, pancreatic duct adenocarcinoma tumor samples from 
patients showed H4K12 and H3K18 acetylations to have a high correlation with tumor 
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stage indicating them as prognostic markers (Juliano et al., 2016). It was recently 
observed that high H4K12ac expressing tumor samples from patients with oral squamous 
cell carcinoma correlated with gender, alcohol consumption and cervical lymph node 
metastasis (Campos-Fernandez et al., 2018). Based on this literature and from results 
which show an increase in H4K12ac after chronic alcohol exposure, it can be concluded 
that upregulated H4K12ac could serve as an important epigenetic marker during chronic 
alcohol abuse (Parira et al., 2017a). 
In order to further understand the function of H4K12ac in MDDCs under alcohol 
exposure, we assayed a newly identified compound NU9056 which was found to inhibit 
histone acetyltransferase TIP60 (Coffey et al., 2012). TIP60 has been previously shown 
to be responsible for histone H4 acetylation specifically modulate H4K12ac amongst other 
acetylation sites (Sanchez-Molina et al., 2014). Therefore, after assaying for the viability 
and toxicity of various concentrations of NU9056 (Parira et al., 2017a), we selected 50nM 
and measured H4K12ac in MDDCs treated chronically with 0.2% EtOH, 50nM NU9056 or 
both and demonstrated that NU9056 could inhibit EtOH-induced H4K12ac and bring it 
back to basal or control levels.   
To summarize, chronic alcohol treatments in human MDDCs, increase total 
histone H3 and H4 quantity and while alcohol downregulates most H3 and H4 
modifications, it upregulates H4K12ac. TIP60 inhibitor NU9056 is able to inhibit EtOH-
induced H4K12ac and bring it back down to basal levels. The significance of this study 
lies in the fact that H4K12ac may be developed and further studied to be an epigenetic 
marker or therapeutic target for AUD’s and NU9056 may be explored as a therapeutic 
drug target. 
 
27 
 
 
 
 
 
 
Figure 1: Chronic alcohol treatment regime maintains 0.2% alcohol concentration 
in human MDDCs.  
Post differentiation, during chronic alcohol treatment, alcohol concentration was measured 
on days 2, 3, 4 and 5, post replenishment with 0.2% Alcohol. The alcohol concentration is 
represented as mean % ± SEM.  
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Figure 2: Chronic alcohol treatment significantly increases histone H3 and H4 
quantity in human MDDCs. 
After 5–7 days of differentiation, MDDCs were treated with 0.1%, and 0.2% alcohol for 5 
days. Panel a: Histone H3 and H4 quantity was analyzed by ELISA-based EpiQuik 
quantification kits independent of its modified state. The values are displayed as percent 
of control ± SEM from at least five independent experiments. Graph indicates H3 at EtOH 
0.1% (111.6 ± 4.858, p = 0.033) and 0.2% (138.1 ± 15.18, p = 0.027), H4 at EtOH 0.2% 
(214.5 ± 33.02, p = 0.0017). 1-way ANOVA was performed to show no significant 
difference between treatments, F (4, 46) = 1.842, P=0.1370. Post-hoc analysis with 
Tukey’s multiple comparisons test showed no significant differences. Statistical 
differences were calculated using student’s t-test when each treatment was individually 
compared to untreated control and 1-way ANOVA followed by Tukey’s multiple 
comparisons test was carried out to test for significance between treatments. Significant 
differences are indicated with * for p≤0.05. 
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Figure 3: Chronic alcohol treatment significantly decreases most histone H3 and 
H4 post-translational modifications but significantly increases acetylation at 12th 
lysine on H4 (H4K12ac).  
Panel (a) Histone extracts from MDDCs chronically treated with EtOH 0.1 and 0.2% were 
analyzed for 21 H3 post-translational modification states. Results show levels of 
significantly altered histone modifications for 0.1 and 0.2% EtOH, presented as 
percentage over untreated control ± SEM from two (EtOH 0.1%) and three (EtOH 0.2%) 
independent experiments. Chronic treatment with 0.2% EtOH in MDDCs showed 
significant downregulation at the sites of H3K4me1 (82.78% ± 2.95, p = 0.004), H3K4me3 
(87.25% ± 3.67, p = 0.025), H3K9me3 (85.97% ± 5.17, p = 0.053), H3K27me2 
(83.54% ± 6.30, p = 0.059), H3K36me3 (78.63% ± 7.17, p = 0.041) and H3K18ac 
(83.62% ± 3.80, p = 0.013) in comparison to untreated control. 2-way ANOVA was 
performed to test for significance between treatments and showed significant column 
factor F (1, 21) = 9.18, P=0.0064. Post-hoc analysis with Tukey’s multiple comparisons 
test did not show any significant differences. Panel (c): Histone extracts from MDDCs 
chronically treated with EtOH 0.2% were analyzed for 10 H4 post-translational 
modification states. Results show levels of significantly altered histone modifications for 
EtOH 0.2% presented as percentage over untreated control ± SEM from 7 (EtOH 0.2%) 
independent experiments. Chronic treatment of the EtOH 0.2% in MDDCs showed 
significant downregulation at H4K5ac (15.44% ± 28.31, p = 0.011), H4K8ac 
(33.69% ± 12.89, p = 0.0002), H4K20m2 (53.63% ± 10.55, p = 0.0009), H4K20m3 
(59.63% ± 10.55, p = 0.019), H4R3m2 (33.45 ± 10.27, p = 0.0003) and H4ser1P 
(49.36 ± 19.86, p = 0.025) and upregulation at H4K12ac (401.64% ± 123.40, p = 0.031), in 
comparison to untreated control. 2-way ANOVA was performed to test for significance 
between treatments and showed significant column factor F (7, 42) = 7.388, P<0.0001. 
Post-hoc analysis with Tukey’s multiple comparisons test was carried out and it showed 
significant difference between control and H4K12ac (P=0.001). Statistical differences 
were calculated using student’s t-test when each treatment was individually compared to 
untreated control and 2-way ANOVA followed by Tukey’s multiple comparisons test was 
carried out to test for significance between treatments. Significant differences are 
indicated with * for p≤0.05. 
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Figure 4: Chronic alcohol induction of H4K12ac was further validated by western 
blot and mass spectrometry analysis (post histone sample preparation in lab, Mass 
spectrometry experiment and analysis was carried out at the MS facility at FIU) .  
Western blot was carried out for H4K12ac and H4 in histone extracts from untreated 
control or 0.2% EtOH treated MDDCs. Panel a- shows representative blot highlighting the 
protein of interest where first 3 lanes have histone extracts from three biological replicates 
of untreated MDDCs and next 3 lanes contain histone extracts from three biological 
replicates of MDDCs chronically treated with 0.2% EtOH. The H4K12ac band appears at 
11 kDa while the H4 band appears at 14 kDa. Panel b - optical density of H4K12ac 
normalized to H4 when analyzed by ImageJ and represented as % control. MDDCs 
chronically treated with 0.2% EtOH (367.3 %± 132.9, p = 0.05) showed a higher 
expression of H4K12ac in comparison to untreated MDDCs (100 %± 15.05).  Western blot 
was carried out with histone extracts for control and 0.2% EtOH treated MDDCs from at 
least 13 different buffy coats. Statistical differences were calculated using t-test when 
compared to untreated control. Typical representative MALDI-FT-ICR MS spectra of the 
10–18 GLGKGGAKR peptide has been shown in Panel c, for control and 0.2% EtOH 
treated MDDC samples (theoretical isotopic pattern is shown for all cases). There is higher 
abundance of the acetylated peptides in the chronic 0.2% EtOH-treated MDDCs relative 
to the control MDDCs (Panel d). The experiment was carried out in 36 µg of total histone 
extracts pooled from untreated and 0.2% EtOH treated MDDCs. 
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Figure 5: Chronic treatment with histone acetyltransferase inhibitor NU9056 (50nM) 
significantly blocks alcohol-induced upregulation in H4K12ac.  
Post differentiation, MDDCs were treated with NU9056 50 nM, EtOH 0.2% or both for 5 
days. Panel a shows H4K12ac quantity from histone extracts as percent (%) of 
control ± SEM from at least three independent experiments. Statistical differences were 
calculated using student’s t-test compared to untreated control (100 ± 22.65) and indicated 
for H4K12ac at NU 50 nM (69.35 ± 15.96), EtOH 0.2% (138.2 ± 18.09, p = 0.05), and EtOH 
0.2% + NU 50 nM (56.27 ± 31, p = 0.04). Interactions between groups were tested by 1-
way ANOVA which gave a F(3,28)=2.494, p = 0.08. Intra-nuclear staining for H4K12ac 
and single cell imaging flow cytometry were also performed and it was carried out at-least 
three times in triplicates. 10,000 events were acquired from live population (eFLUOR450 
dye) per sample. Controls with secondary (2°) antibody (Ab) only and isotype staining 
were also analyzed. Panel b shows a representative overlay of histogram of intensity of 
channel 2 (FITC) for each treatment shown in legend on the histogram. Panel d shows the 
percentage of FITC positive (H4K12ac expressing cells). 2° Ab control showed 
(0.02% ± 0.009) H4K12ac positive population. Isotype control showed (0.34% ± 0.001) 
positive for H4K12ac. NU 9056 (50 nM) (62.7% ± 3.5, p = 0.004) reduced H4K12ac 
positive cells compared to control (74.93% ± 1.73) while 0.2% EtOH increased H4K12ac 
positive cells (82.9% ± 0.84, p = 0.0008) compared to control. 0.2% EtOH and NU9056 
(50 nM) reduced H4K12ac positive cells (68.21% ± 2.57, p = 0.0005) compared to cells 
treated with 0.2% EtOH alone. 2-way ANOVA gave a significant value of F(3,30)=14.42, 
p < 0.0001. Panel c shows MFI of H4K12ac population from each treatment after 
background subtraction. 0.2% EtOH + NU9056 50 nM (133163 ± 23359, p = 0.0002) show 
significantly reduced MFI compared to 0.2% EtOH (203686 ± 41517) treated MDDCs only. 
2-way ANOVA showed significant row factor (F(10,30)=36.77, p<0.0001) and significant 
column factor (F(3,30)=8.72, p=0.0003). Panel e shows representative single cell images 
from experiments where live cells were acquired based on staining with fixable viability 
dye eFLUOR 450. Panel f shows representative single cell images confirming nuclear 
staining with H4K12ac antibody based on DAPI co localization with H4K12ac. 
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CHAPTER 4: Research Question 2: Do these epigenetic changes under chronic 
alcohol treatment modulate human MDDC function? 
 
4.1 Introduction 
Dendritic cells, the sentinels of the human immune system, professional antigen 
presenting cells are crucial in initiating and determining immune responses (Boltjes and 
van Wijk, 2014). The primary functions of dendritic cells lie in antigen uptake and 
presentation with the help of cell surface markers and receptors, production of cytokines 
and chemokines and finally launching an immune response to foreign antigens (O'Keeffe 
et al., 2015). As previously discussed, several studies have shown alcohol exposure to 
modulate their functional properties but how epigenetic changes due to alcohol exposure 
modulate DC functionality is not completely understood. Previous researchers have 
studied certain epigenetic mechanisms of DC function, for example, lysine methyl 
transferases (KMT) especially KMT1c is an important component towards monocyte 
differentiating to DC’s (Wierda et al., 2015). Another study showed that histone 
modifications of H3K4me3 and H3K27me3 may be an important player towards DC 
differentiation and function in a tumor like or inflammatory environment (Mei et al., 2014). 
To further understand the functional relevance of alcohol induced H4K12ac towards 
MDDC functionality, this aim will look at cell surface markers and receptor expression on 
MDDCs under alcohol exposure and how the cytokine or chemokine secretions by MDDCs 
get modulated by the same. 
As previously elaborated in the introduction cannabinoid receptors have been 
indicated to be involved with mechanisms of alcohol action. However, when it comes to 
understanding the epigenetic basis of this interaction, not much is known in that aspect. A 
few studies have explored to gain a deeper understanding of this association from 
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epigenetics point of view. One such study on fetal alcohol spectrum disorder (FASD) 
showed that, when CB1 receptor was knocked out in neonatal mice, they were protected 
from alcohol’s debilitating effects on DNA methyltransferases DNMT1, DNMT 3A and 
overall DNA methylation (Nagre et al., 2015). Another study in a mouse model of FASD 
showed ethanol exposure caused upregulation of H4K8 acetylation at the CB1 receptor 
exon further causing neurobehavioral abnormalities in mice (Subbanna et al., 2014).   
Previous reports from our lab have shown acute alcohol exposure was able to increase 
expression of cannabinoid receptors CB2 and GPR55 in primary human MDDCs (Agudelo 
et al., 2013). Additionally, in MDDCs derived from alcohol users, CB2 and GPR55 were 
found to be increased in expression compared to MDDCs derived from non-users 
(Agudelo et al., 2013). To further understand the epigenetic basis of this interaction 
between alcohol and cannabinoid receptors in MDDCs, the newly established role of 
H4K12ac under chronic alcohol exposure  was studied for its ability to modulate 
cannabinoid receptor expression. These studies were first carried out at acute levels using 
ChIP-PCR and reducing acetylation at H4K12 through NU9056 and siRNA, and results 
showed that after acute alcohol levels, H4K12ac was associated with an increase in 
GPR55 expression in primary human MDDCs treated acutely with alcohol (Castillo-
Chabeco et al., 2018). However, whether alcohol’s modulation of H4K12ac was 
associated with regulation of cannabinoid receptor expression even after chronic alcohol 
treatments was yet to be studied.  
4.2 Methods 
4.2.1 Cell surface marker study for chronic alcohol treatment – To understand if 
chronic treatment with alcohol is causing dendritic cells to differentiate and mature further, 
MDDCs were immune-phenotyped for monocyte surface marker CD14 (Ziegler-Heitbrock 
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and Ulevitch, 1993) and dendritic cell surface marker CD11c (Singh-Jasuja et al., 2013). 
They were labeled with an anti-CD14-APC cy7 antibody (eBioscience) and anti-CD11c-
APC antibody (eBioscience) followed by acquisition with FlowSight single cell imaging flow 
cytometer (Amnis, EMD Millipore). Data were analyzed using Ideas image analysis 
software. 
4.2.2 Cytokine array and MCP2 ELISA The expression of 48 inflammatory cytokines was 
analyzed according to manufacturer instructions with the RayBiotech inflammation arrays 
(RayBiotech, Norcross, GA, USA) as previously described by us (Agudelo et al., 2013, 
Parira et al., 2017c, Parira et al., 2017a). Briefly, supernatants from cells after 5-day post-
treatment with NU9056, 0.2% EtOH and 0.2% EtOH + NU9056 and an untreated control 
were assayed for the experiment. MCP-2 ELISA was carried out using MCP-2 ELISA kit 
(RayBiotech) as per manufacturer’s instructions (Parira et al., 2017a). 
4.2.3 Gene quantification of GPR55. Total RNA was isolated from treated or untreated 
MDDCs using commercially available DNA/RNA/Protein isolation TriplePrep kit (GE 
healthcare). Following isolation, RNA was reverse transcribed to cDNA (Agilent 
Technologies) and cDNA was used to amplify GPR55 and 18srRNA using primers GPR55 
(Hs00271662_s1, Thermofisher Scientific) and 18srRNA (#4333760F, Thermofisher 
Scientific). Relative mRNA species expression was quantitated and the mean fold change 
in expression of the target gene was calculated using the comparative CT method and 
expressed as Transcript Accumulation Index or TAI. 18s rRNA was used as endogenous 
control.  
4.2.4 Protein quantification of GPR55: western blotting and single cell imaging flow 
cytometry Total protein was isolated from treated or untreated MDDCs using 
commercially available RNA/Protein isolation kit (GE healthcare). GPR55 protein 
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expression was measured by western blotting with 30ug of protein isolate, using anti-
GPR55 antibody (Bios) normalized to GAPDH (Sigma-Aldrich). GPR55 was also 
quantified by single-cell imaging flow cytometry. 1 × 106 cells were stained with AF-647-
labeled GPR55 antibody (Bios). Rabbit isotype control antibody (Thermo Fisher) was also 
used. Intra-cellular staining for H4K12ac was carried out using Fix/Perm buffer kit (BD 
Biosciences) following the manufacturer’s protocol. Cells were first stained with fixable 
viability dye eFLUOR®450 (eBioscience) to gate on live cell population during image 
acquisition. Image acquisition by Amnis® FlowSight® Imaging Flow Cytometer and 
analysis by IDEAS® image software was carried out as previously described by us 
(Figueroa et al., 2016, Parira et al., 2017c) (Parira et al., 2017a). For each experiment, 
from all events collected, AF647 positive cells were gated from single cells.  
4.2.5 Treatment with CID and NU9056 and GPR55 protein quantification. Treatment 
with NU9056 was carried out according to a previously elucidated method and 
concentration. Optimum concentration for the GPR55 antagonist, CID16020046 (CID) 
(Tocris) was selected by XTT viability and Lactate dehydrogenase toxicity assay 
(Supplementary Figure S1). MDDCs were pre-treated with 5 uM CID followed by chronic 
treatment with 0.2% EtOH for MDDCs receiving both treatments. Post chronic treatment, 
GPR55 was quantified using single cell imaging flow cytometry. Data were analyzed as 
previously elucidated.  
4.2.6 Statistical analysis. Data are expressed as mean ± SEM. Experiments were 
performed at least three times or otherwise indicated in the figure legends. Statistical 
analysis like student’s t-test and 1-way and/or 2-way ANOVA were done using either 
Microsoft Excel or GraphPad Prism software. For more than one treatment groups, post-
hoc analysis like Tukey’s multiple comparisons test was also carried out. Values of the 
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same have been expressed as F (DFn, DFd). P values were considered significant when 
they were ≤ 0.05. 
4.3 Results 
4.3.1 Chronic alcohol treatment does not affect the population of dendritic cells in 
late stage of differentiation. 
During chronic alcohol treatment, expression levels of monocytic marker CD14 and 
dendritic cell marker CD11c was assessed by single-cell imaging flow cytometry. They 
were measured at Day 0 before starting alcohol treatment, followed by measurement at 
Day 3 and Day 5 post-treatment. Concurrent with our previous publication (Figueroa et 
al., 2016), as seen in figure 6 panel a, purely monocytic cell population or CD14 positive 
population form the smallest percentage of the total cell population. Even during chronic 
treatment, at Day 3 and Day 5 CD14 positive population remain under 10% of the total 
population with no significant differences between alcohol-treated and untreated MDDCs. 
As shown in panel B, dendritic cells in early stages of differentiation characterized by 
CD11c and CD14 double positive cell population are significantly high in 0.2 % EtOH 
treated MDDCs at both Day 3 (26.9% ± 0.7, p=0.03) and Day 5 (21.2% ± 1.6, p=0.02) 
compared to untreated MDDCs on Day 3 (14.8% ± 3.7) and Day 5 (12.9 % ± 1.9) 
respectively.   As shown in panel C, the majority of cell population (57.4%) fall under 
dendritic cells that are in the late stage of differentiation as characterized by CD11c 
positive and CD14 negative and almost 80% of cell population is CD11c positive hence 
dendritic cells in either early or late stages of differentiation. However, there is no 
significant difference between 0.2% EtOH treated and untreated MDDCs at Day 3 or 5 of 
treatment. 
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4.3.2 Inhibition of H4k12ac with NU9056, modulates cytokines and chemokines 
induced by alcohol treatments in human MDDCs. To understand the role of chronic 
alcohol treatment and H4K12ac in inflammation in MDDCs, 48 inflammatory cytokines and 
chemokines were studied by using an inflammation array. Cell culture supernatants from 
untreated MDDCs or MDDCs treated EtOH, NU9056 or both were analyzed for secreted 
inflammatory cytokines and chemokines. As shown in figure 7, panel a, a graphical 
representation of optical density values show treatment with 0.2% EtOH significantly 
upregulates ICAM-1 (4.71 ± 0.42, p = 0.0007) and IL-10 (5.008 ± 0.89, p = 0.027). While 
inhibition of H4K12ac by NU9056 (50 nM) significantly upregulates ICAM-1 (7.37 ± 1.16, 
p = 0.002), IL-6 (4.55 ± 1.21, p = 0.015), IL-10 (4.13 ± 1.03, p = 0.046), IL-15 (4.33 ± 1.84, 
p = 0.062), IL-16 (2.62 ± 1.02, p = 0.059) and IP-10 (4.15 ± 0.69, p = 0.002) when 
compared to untreated control. In addition, when the cells were treated with a combination 
of 0.2% EtOH and NU9056, there was a significant upregulation of ICAM-1 (10.43 ± 2.42, 
p = 0.011), IL-10 (4.35 ± 0.55, p = 0.023), IL-15 (6.68 ± 1.01, p = 0.0009), IL-16 
(1.94 ± 0.35, p = 0.0004) and IP-10 (3.95 ± 0.35, p = 0.0002) when compared to untreated 
control. Statistical analysis between MDDCs co-treated with 0.2% EtOH + NU9056 versus 
MDDCs treated with only 0.2% EtOH revealed a significant upregulation of IL-15 
(p = 0.036), RANTES (p = 0.014), TGFβ−1 (p = 0.0008) and TNFα (p = 0.028) as shown in 
figure 7 panel c, and significant downregulation of MCP-2 (p = 0.016) as shown in figure 
7, panel d. Representative blots for each treatment have been shown in panel b. To further 
validate the modulation of MCP-2 by H4K12ac, MCP-2 levels were measured by ELISA 
(panel e) in cell culture supernatants. The combination of 0.2% EtOH and NU9056 50 nM 
(321.64 pg/mL ± 13.50, p = 0.03) significantly reduced MCP-2 levels compared to 0.2% 
EtOH treatment alone (401.75 pg/mL ± 28.22). (Parira et al., 2017a) 
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4.3.3 Chronic alcohol treatments increase gene and protein expression of GPR55. 
In order to understand the effect of chronic alcohol treatment on GPR55 gene and protein 
expression,  post-treatment, cells were either stained for single cell imaging flow cytometry 
or total RNA and protein was isolated to perform gene expression studies through qPCR 
and protein expression studies through western blotting respectively. Panel a shows 
transcript accumulation index of GPR55 measured by qPCR analysis where 0.2% EtOH 
treated MDDCs (1.64±0.24, p=0.02) show significantly increased GPR55 gene 
transcription compared to untreated MDDCs. To confirm GPR55 upregulation in MDDCs 
chronically treated with 0.2% EtOH, western blot was performed using total protein 
extracts and GPR55 protein levels from treated samples and controls were normalized to 
GAPDH. Panel b shows the optical density of GPR55 normalized to GAPDH where 0.2% 
EtOH (1.7±0.1, p=0.0006) shows significantly higher GPR55 protein expression compared 
to untreated MDDCs (0.9±0.06).  Panel c shows a representative blot picture.  As shown 
in panel d, 0.2% EtOH treated MDDCs have a significantly higher percentage of cells 
(59.7%±5.5, p=0.0005) expressing GPR55 compared to untreated MDDCs (30.8%±4). 
Panel e shows a representative overlay histogram of the intensity of GPR55.  
Representative single cell images are shown in Panel f. 
4.3.4 GPR55 antagonist CID16020046 reduces chronic alcohol-induced protein 
expression of GPR55. Since chronic alcohol treatment was able to increase the GPR55 
gene and protein expression, we wanted to further understand the effect of blocking 
GPR55 expression. In order to block GPR55 expression, we selected GPR55 antagonist 
CID16020046 (CID) which was found to inhibit LPI induced NFAT, NFB, calcium release 
and GPR55 internalization in HEK293 cells (Kargl et al., 2013). We carried out viability 
and toxicity studies (Supplementary Figure S1) to select an optimum concentration of 5uM 
of CID. Post-treatment of MDDCs with 0.2% EtOH, or 5uM CID or combination of both, 
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immunostaining with anti-GPR55-AF647 was carried out and GPR55 expression levels 
were measured using single cell imaging flow cytometry. As shown in Figure 9 panel a, 
MDDCs treated with 0.2% EtOH + 5uM CID (12.4±3.8%, p=0.0001) significantly reduces 
percentage of GPR55 positive cells compared to 0.2% EtOH treated MDDCs only 
(59.7%±5.5). Thus, this data showed the ability of combination treatment of EtOH and CID 
to reduce EtOH induced GPR55. Panel b shows a representative overlay histogram of 
GPR55 intensity. Panel c shows representative single cell images. 
4.3.5 H4K12ac antagonist NU9056 decreases chronic alcohol-induced protein 
expression of GPR55. To further understand if acetylation at H4K12 is associated with 
GPR55 expression, we carried out GPR55 quantification studies after MDDCs were 
treated with HAT inhibitor NU9056 and EtOH or combination of both. Post-treatment of 
MDDCs with 0.2% EtOH, or 50nM NU9056 or combination of both, immunostaining with 
anti-GPR55-AF647 was carried out and GPR55 expression levels were measured using 
single cell imaging flow cytometry. As shown in Figure 10 panel a, treatments with 0.2% 
EtOH + 50nM NU9056 (14.4±8.3%, p=0.0001) significantly reduces the percentage of 
GPR55 positive cells compared to 0.2% EtOH-treated MDDCs only (59.7%±5.5). Thus, 
these data showed the ability of combination treatment of EtOH and NU9056 to block 
EtOH induced GPR55. Panel b shows a representative overlay histogram of GPR55 
intensity. Panel c shows representative single cell images. 
4.4 Discussion 
In order to understand how chronic alcohol treatments modulate MDDC 
functionality, we first assessed the purity of the dendritic cells that were differentiated from 
monocytes and then treated chronically with alcohol. Other studies have shown alcohol 
treatments to modulate differentiation and maturation of immune cells (Zhang et al., 2015, 
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Saha et al., 2015). We have previously shown CD11c a dendritic cell marker and CD14 a 
monocytic cell marker (Figueroa et al., 2016) as effective cell surface markers to 
understand the purity of dendritic cells in case of processes that differentiate dendritic cells 
from monocytic cells (Wolkow et al., 2018). CD11c on antigen presenting cells has been 
shown to interact with Th17 cells and help in expression of inflammatory chemokines 
(Paterka et al., 2016). CD11c along with CD11b has also been shown to play a role in DC 
tolerance (Wang et al., 2016). Amongst several functions of CD14 like serving as 
coreceptor for TLR4 and enabling cellular response to low dose of LPS (Zanoni and 
Granucci, 2013), recently it has been elucidated to initiate inflammosome dependent 
phagocytosis after incurring inflammatory lipids (Zanoni et al., 2017).  Our results showed 
(Figure 6), that about 80% of cells are CD11c+ hence dendritic cells in the total cell 
population. About 60% were in the late stages of differentiation (CD11c+ CD14-) and there 
was no significant difference between those cell populations. About 20% were in the early 
stages of differentiation (CD11c+ CD14+) which showed a significant difference between 
treatments.  Hence, even though there may be some variations due to studies which have 
dendritic cells in the early stages of differentiation or monocytic cells included in them, it 
may be outweighed by the majority of dendritic cells in the late stages of differentiation. 
Overall purely monocytic cells or CD14+ forms only about 10% of the total population of 
cells and CD11c- CD14- cells form about 10% of the total population of cells used for the 
experiment hence the effects due to the same may be negligible. Previous studies have 
reported chronic alcohol exposure for 3 months in rhesus macaques reduced number of 
myeloid dendritic cells (HLA-DR+CD11c+CD123-) in both PBMCs and bone marrow cells 
(Siggins et al., 2009). In yet another study, BALB/c mice that were fed ethanol for 11 days 
showed increased CD11c on dendritic cells and decreased IL-6, IL-12, IL-17A, and IFN-
gamma and increased IL-13 cytokine production in response to ovalbumin stimulation 
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(Heinz and Waltenbaugh, 2007). An interesting clinical study showed men living with HIV 
and concomitant alcohol use showed increased presence of soluble CD14 in blood plasma 
(Monnig et al., 2016). Another study reported that chronic alcohol use reduced 
CD14+CD16- subset of peripheral monocytes and increased CD14dimcd16+ subset, 
overall increasing IL-6 and TNF production (Donnadieu-Rigole et al., 2016). These studies 
further show alcohol associated modulation in monocytic/dendritic cell surface markers 
and modulation of function of the same.  
To understand if H4K12ac serves an inflammatory role, we measured 48 
inflammatory cytokines and chemokines in MDDCs untreated or chronically treated with 
0.2% EtOH, NU9056 or 0.2% EtOH + NU9056. NU9056 in combination with 0.2% EtOH 
treatment enhanced the effects of EtOH on cytokine production by upregulating the 
secretion of IL-15, RANTES, TGFβ−1 and TNFα compared to EtOH 0.2% while blocking 
the secretion of MCP-2 compared to 0.2% EtOH treatment, suggesting a partial 
inflammatory role of H4K12ac (Parira et al., 2017a). Histone acetylations are typically 
associated with increased gene and protein expression thereby positively regulating 
genes (Krebs and Peterson, 2000). A study showed, chronic binge alcohol increases gene 
expression of pro-inflammatory CCL2, CCL8, CX3CL1, SELE, HP, and TNFRS10A and 
expression of pro-fibrotic genes in the extra cellular matrix like TIMP-1, MMP 2, and MMP 
9 mRNA in skeletal muscle tissue of SIV infected macaques (Dodd et al., 2014).  
Alcohol has been shown to modulate cannabinoid receptors (Agudelo et al., 2013, 
Al Mansouri et al., 2014, Zheng et al., 2015); however, the mechanism behind this 
association is still being investigated. Some studies have explored epigenetic mechanisms 
behind this association (Subbanna et al., 2014, Nagre et al., 2015); however, many 
detailed studies are needed to understand the alcohol-cannabinergic pathway in-depth. 
45 
 
We recently published that chronic alcohol treatment was able to upregulate acetylation 
at H4K12 (Parira et al., 2017a) and acute alcohol treatment was able to upregulate 
H4K12ac at GPR55 gene region (Castillo-Chabeco et al., 2018). To further validate this 
and to understand the role of chronic alcohol treatment in GPR55 expression, we 
measured the GPR55 gene and protein expression through real-time qPCR, western 
blotting and single cell imaging flow cytometry. The results confirmed chronic alcohol 
treatment was able to upregulate gene and protein expression of GPR55 as previously 
demonstrated by us in MDDCs treated acutely with alcohol and MDDCs from self-reported 
alcohol users. Most commonly, increased histone acetylation corresponds to increase in 
gene transcription and further increased translation resulting in increased protein 
expression (Krebs and Peterson, 2000). Since increased acetylation of H4K12 is 
accompanied by increased GPR55 gene and protein expression it is possible that chronic 
alcohol treatment induced H4K12ac may be at least partially regulating expression of 
cannabinoid receptor GPR55. Previous reports have also shown increased intragenic 
histone acetylation to result in increased gene expression (Johansson et al., 2015). There 
may also be other factors that are contributing towards its upregulated expression like 
increased acetylation at promoter regions and other epigenetic factors like micro-RNAs. 
We further wanted to confirm the nature of this gene regulation. We tested the ability of 
GPR55 antagonist CID to be able to block chronic alcohol-induced GPR55 expression 
and found that even though CID by itself does not affect GPR55 protein expression 
(corroborated by previously published reports where CID prevented GPR55 internalization 
in HEK293 cells (Kargl, 2013 #433)) and keeps it at the same levels as untreated MDDCs, 
in combination with EtOH it decreases GPR55 expression compared to EtOH treated 
MDDCs (Figure 9). This decreasing effect may be explained by drug-drug interactions 
between CID and EtOH. Pharmacodynamic interactions between natural and synthetic 
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cannabinoids and drugs of abuse like alcohol has been shown to modulate overall 
interaction and functionality as reviewed recently (Arellano et al., 2017). Similar effects of 
decrease in GPR55 expression due to alcohol exposure in combination with GPR55 
antagonist CBD was demonstrated in mice where CBD reduced alcohol induced 
hypothermia and handling issued convulsion (Viudez-Martinez et al., 2018). However, in 
order to understand how CID by itself does not reduce GPR55 expression but in 
combination with alcohol is able to reduce it needs further investigation.  
 Once we confirmed that CID revered/ reduced alcohol effects on GPR55, we wanted to 
study if alcohol-induction of GPR55 was due to acetylation or correlated to alcohol-induced 
H4K12ac; therefore we used previously studied and published TIP60/HAT inhibitor which 
was found to inhibit alcohol-induced H4K12ac (Parira et al., 2017a). We measured GPR55 
protein levels using NU9056 alone or in combination with EtOH and found that in 
combination with EtOH it reduces GPR55 protein levels compared to EtOH treated 
MDDCs. This further confirmed the association between alcohol-induced H4K12ac and 
GPR55 expression. It may be noteworthy to mention here that even though NU9056 alone 
did not have a significant downregulation on GPR55 compared to untreated MDDCs, when 
compared to CID, it showed a lower level of GPR55 expression implying that blocking 
TIP60 causes a stronger blocking effect on GPR55 expression inhibiting alcohol-effects 
on GPR55. This further sheds some light on to the mechanism lying underneath this 
associative pathway. In conclusion, chronic alcohol treatment was able to upregulate 
H4K12ac with a concomitant increase in GPR55 gene and protein expression. 
Additionally, GPR55 antagonist CID was able to decrease alcohol-induced GPR55 and 
TIP60/HAT inhibitor NU9056 was able to reduce alcohol-induced GPR55. However further 
experiments are needed to understand this pathway in-depth. Some of the future 
directions are to carry out siRNA-mediated knockdown of TIP60 during chronic alcohol 
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treatment conditions, which may give more concrete answers to our questions. Analyzing 
H4K12ac levels at GPR55 promoter region using chromatin immunoprecipitation (ChIP) 
will also help us further understand its relationship with GPR55 gene regulation. When it 
comes to understanding the epigenetic status of GPR55 gene and promoter, not much is 
known in terms of histone post translational modifications but a recent report showed 
GPR55 promoter to have heavy DNA methylation regions in colon cancer cell lines with 
lower degree of methylation in the gene body and 5’ UTR (Hasenoehrl et al., 2018).  We 
were recently able to show upregulated H4K12ac at the gene region of GPR55 in MDDCs 
after acute alcohol exposure (Castillo-Chabeco et al., 2018), however we need to carry 
out these studies in MDDCs after chronic alcohol exposure to understand these epigenetic 
effects in depth.
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Figure 6: Chronic alcohol treatment does not affect population of dendritic cells in 
late stages of differentiation.  
Post differentiation of MDDCs, single cell imaging flow cytometry analysis for cell surface 
markers CD11c and CD14 was carried out at three time points. Day 0 (before starting 
chronic treatment, Day 3 and Day 5 of chronic alcohol treatment). 1 x 106 cells were 
stained with anti-CD11c (APC)-red (CH11) and anti-CD14 (APC-cy7)-pink(CH12) followed 
by staining with DAPI. Out of 10,000 images acquired, DAPI negative or live cell population 
was gated. From live cell population, CD14+, CD11c+CD14- and CD11c+CD14+ cells 
were gated utilizing scatter plots. Percent positive cells were graphed in panels a, b and 
c. Panel a shows CD14 positive or monocytic cell populations at day 0, 3 and 5. no 
significant differences were found. Panel b shows CD11c+CD14+ or early dendritic cells 
or dendritic cells in early stages of differentiation. Early dendritic cells characterized by 
CD11c and CD14 double positive cell population are significantly high in 0.2 % EtOH 
treated MDDCs at both Day 3 (26.9% ± 0.7, p=0.03) and Day 5 (21.2% ± 1.6, p=0.02) 
compared to untreated MDDCs on Day 3 (14.8% ± 3.7) and Day 5 (12.9 % ± 1.9) 
respectively. Panel c shows CD11c+CD14- or late dendritic cells or dendritic cells in late 
stages of differentiation. No significant differences were found. Panel d shows a 
representative histogram of intensity of DAPI and gating of alive cell population. Panel e 
shows representative single cell images. Panel f shows a representative scatter plot of 
CD11c or CH11 and CD14 or CH12 intensity with gating of four different subtypes of cell 
population indicated as CH11+CH12- (57.4%), CH11+CH12+ (24.9%), CH11-CH12+ 
(9.4%) and CH11-CH12- or double negative (8.3%).  The experiments were performed 
from at least 3 different buffy coats. Significance was calculated by students T-test and 
indicated by * for p≤0.05.   
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Figure 7: Inhibition of H4k12ac with NU9056, modulates cytokines and chemokines 
production by alcohol treatments in human MDDCs.  
 
After 5-7 days of differentiation, MDDCs were treated with NU9056 50nM, 0.2% EtOH or 
both for 5 days. Supernatants collected were analyzed for 48 inflammatory cytokines and 
chemokines. Array blots were analyzed using ImageJ software. Panel a shows graphical 
representation of optical density (OD) values post background correction (subtracting of 
mean negative from OD) ± SEM. Represented data is from 3 blots for untreated control, 
2 blots each for treatment with 0.2% EtOH alone, treatment with NU9056 alone, and 
treatment with 0.2% EtOH plus NU9056. Cytokines chosen to be presented in the graph 
were selected on the basis of fold change (2 folds or more) compared to control. Panel b 
shows representative blots with boxes highlight cytokines shown in panel c. Each cytokine 
is detected in duplicates within each blot. Panel c shows optical density values for 
cytokines IL-15, RANTES, TGF-β1 and TNF-α. Panel d shows optical density values for 
MCP2. Statistical analysis between MDDCs co-treated with 0.2% EtOH + NU9056 versus 
MDDCs treated with only 0.2% EtOH to reveal a significant upregulation of IL-15 
(p = 0.036), RANTES (p = 0.014), TGFβ−1 (p = 0.0008) and TNFα (p = 0.028) as shown in 
panel c, and significant downregulation of MCP-2 (p = 0.016) as shown in panel d. 
Statistical differences were calculated using student’s t-test when individually compared 
to untreated control and indicated with a * (compared to control) and # (between 
treatments) for significant p value. Data is represented as Mean ± SEM. Two-way ANOVA 
was carried out to test for interaction giving a significant value (F(27, 120)=3.521, 
p<0.0001). In panel e, MCP-2 ELISA was carried out from cell culture medium at least 
three times in duplicates. Values detected in pg/mL are as follows, untreated control 
(322.4 ± 25.04), NU9056 50 nM (317.5 ± 14.3), 0.2% EtOH (401.7 ± 28.2) and 0.2% 
EtOH + NU9056 50 nM (321.6 ± 13.5, p = 0.03). The experiment was carried out at least 
thrice in duplicates. Two-way ANOVA was carried out to test for interaction which gave a 
significant column factor of F(3,21)=3.542, p=0.03. Data is represented as Mean ± SEM. 
Significant differences are indicated with * for p≤0.05. 
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Figure 8: Chronic alcohol treatments increase gene and protein expression of 
GPR55.  
 
MDDCs were chronically treated with 0.2% EtOH. Post 5 days, either total RNA and 
protein was isolated from the cells for qPCR and immunoblotting analysis respectively or 
single cell imaging flow cytometry was carried out. Panel a shows transcript accumulation 
index (Wang et al.) of GPR55 measured by qPCR analysis. 0.2% EtOH treated MDDCs 
(1.64±0.24, p=0.02) show significantly increased GPR55 gene transcription compared to 
untreated MDDCs.  Panel b shows optical density of GPR55 normalized to GAPDH. 0.2% 
EtOH (1.7±0.1, p=0.0006) shows significantly higher GPR55 protein expression compared 
to untreated MDDCs (0.9±0.06). Panel c shows representative immunoblot. 1x10
6
 MDDCs 
were stained with fixable viability dye eFLUOR450 and anti-GPR55-AF647 using 
intracellular cell staining protocol and single cell imaging flow cytometry was carried out. 
10,000 live cell images were acquired using FlowSight and data was analyzed using Ideas 
Application where AF647 positive cells were gated from total single cells and represented 
as % gated cells in panel d. 0.2% EtOH treated MDDCs have a significantly higher 
percentage of cells (59.7%±5.5, p=0.0005) expressing GPR55 compared to untreated 
MDDCs (30.8%±4). Panel e shows representative overlay histogram of intensity of AF647 
for all treatments. Panel f shows representative single cell images. All experiments were 
performed at least thrice. Data is represented as Mean ± SEM. Statistical significance was 
calculated using Students T-test with EtOH 0.2% compared to control. and p value 
considered significant at p≤0.05 and annotated as *. 
 
 
  
54 
 
55 
 
Figure 9: GPR55 antagonist, CID16020046, decreases chronic alcohol-induced 
protein expression of GPR55.  
 
Post chronic treatment of MDDCs with 0.2% EtOH, or 5uM CID or combination of both, 
immunostaining with anti-GPR55-AF647 was carried out and GPR55 expression levels 
were measured using single cell imaging flow cytometry. As shown in panel a, MDDCs 
treated with 0.2% EtOH + 5uM CID (12.4±3.8%, p=0.0001) significantly reduces 
percentage of GPR55 positive cells compared to 0.2% EtOH treated MDDCs only 
(59.7%±5.5). 1-way ANOVA showed significant difference between treatments 
(F(3,40)=19.69, p<0.0001). Panel b shows representative overlay histogram of intensity 
of GPR55 or AF647 for all treatments. Panel c shows representative single cell images. 
The experiment was carried out at least thrice in duplicates. Data is represented as Mean 
± SEM. Statistical differences were calculated using student’s t-test when each treated 
samples were individually compared to untreated control and 1-way ANOVA followed by 
Tukey’s multiple comparisons test to test for significance between treatments, significant 
differences are indicated with * for p≤0.05. 
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Figure 10: H4K12ac antagonist, NU9056, decreases chronic alcohol-induced protein 
expression of GPR55.  
 
Post-treatment of MDDCs with 0.2% EtOH, or 50nM NU9056 or combination of both, 
immunostaining with anti-GPR55-AF647 was carried out and GPR55 expression levels 
were measured using single cell imaging flow cytometry. As shown in panel a, MDDCs 
treated with 0.2% EtOH + 50nM NU9056 (14.4±8.3%, p=0.0001) significantly reduces 
percentage of GPR55 positive cells compared to 0.2% EtOH treated MDDCs only 
(59.7%±5.5). 1-way ANOVA showed a significant difference between treatments 
(F(3,34)=12.78, p<0.0001). Panel b shows a representative overlay histogram of GPR55 
intensity. Panel c shows representative single cell images. . The experiment was carried 
out at least thrice. Data is represented as Mean ± SEM. Statistical differences were 
calculated using student’s t-test when each treated samples were individually compared 
to untreated control and 1-way ANOVA followed by Tukey’s multiple comparisons test to 
test for significance between treatments, significant differences are indicated with * for 
p≤0.05. 
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Supplementary Figure S1: XTT and LDH assay point towards CID5uM as optimum concentration for chronic treatments: Panel 
a: XTT assay show, 15uM CID (72±4.3%, p=0.0002) causes significantly reduced viability in MDDCs compared to control 
(100±4.8%). Panel b: LDH assay show no significant differences between untreated and treated MDDCs. The values shown on the 
graph for LDH activity (mU/ML) are as follows: Positive control (1020±2.9), Control (30.4±1), 1uM CID (35.4±0.41), 2.5uM CID 
(38.5±0.2), 5uM CID (30.5±0.9), 10uM CID (32.3±0.8) and 15uM CID (22.5±0.1). All experiments were performed at least twice in 
duplicates. Statistical significance was calculated using Students T test and p value considered significant at p≤0.05 and annotated 
as *. 
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CHAPTER 5: Research Question 3: What are the mechanisms that underlie the 
functional effects of chronic alcohol exposure of human MDDCs? 
 
5.1 Introduction 
Amongst several adverse effects of alcohol abuse, inflammation, and oxidative 
stress have gained importance over time so much so that alcoholism has been referred to 
as a systemic proinflammatory condition (Gonzalez-Reimers et al., 2014). While acute 
alcohol inhibits the inflammatory response, chronic alcohol abuse enhances inflammatory 
responses (Szabo and Saha, 2015). Apart from enhancing expression of proinflammatory 
responses, alcohol has also been discussed to suppress anti-inflammatory cytokines 
(Szabo and Saha, 2015). Apart from inflammation, oxidative stress or production of 
reactive oxygen species (ROS) is often linked to inflammation and even towards 
exacerbating inflammation thereby contributing towards pathophysiology of several 
debilitating diseases (Lugrin et al., 2014). Alcohol abuse has also been shown to cause 
oxidative stress and ROS production through its metabolism or through inflammation 
which has been studied as one of the causes of alcoholic liver disease (Li et al., 2015). 
Amongst different therapeutic drug targets for AUD’s, cannabinoids have been 
investigated for the same potential and have been discussed to have opposing neuro-
immunomodulatory effects compared to alcohol (Nair et al., 2015). While CB2 receptor 
agonists have been shown to reduce pain and inflammation related adversities in chronic 
alcohol or high-fat diet-induced pancreatitis (Zhang et al., 2014a), the GPR55 antagonist 
CID has been shown to protect against intestinal inflammation (Stancic et al., 2015) and 
reduce chemo-resistance in pancreatic cancer cells (Singh et al., 2016). The GPR55 
antagonist Cannabidiol (CBD) was also recently shown to reduce ethanol consumption, 
motivation and relapse in mice (Viudez-Martinez et al., 2018). 
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Alcohol users have shown upregulated inflammatory cytokines and chemokines 
compared to non-users or controls (Nair et al., 2015).  Further, we have also previously 
shown that acute alcohol exposure upregulates ROS production in human neuronal cells 
(Agudelo et al., 2011). In this current chapter, we wanted to further study the mechanisms 
that underlie the functional effects of chronic alcohol exposure of human MDDCs. To keep 
this aim in mind, we studied MCP-2 levels further by single cell imaging flow cytometry. 
We further studied oxidative stress or ROS production in human MDDCs treated with 
NU9056. To focus further in the GPR55 cell signaling, we also studied cyclic AMP levels 
in MDDCs. In all assays, treatments of NU9056 were incorporated to understand the role 
of H4K12ac and CID was incorporated to understand the role of GPR55. 
5.2 Methods 
5.2.1 MCP2 single cell imaging flow cytometry 1 × 106 cells were stained with primary 
MCP2-FITC labeled antibody (Novus) following manufacturers protocol for the 
fixation/permeabilization kit (BD Biosciences). Cells were first stained with fixable viability 
dye eFLUOR®450 (eBioscience) to gate on live cell population during image acquisition. 
Image acquisition by Amnis® FlowSight® Imaging Flow Cytometer and analysis by 
IDEAS® image software was carried out as previously described by us (Figueroa et al., 
2016, Parira et al., 2017c) (Parira et al., 2017a). For each experiment, from all events 
collected, FITC positive cells were gated from single cells. 
5.2.2 Single cell imaging flow cytometry study of ROS Post chronic treatments (0.2% 
EtOH, NU9056 and CID for 5 days), MDDCs were harvested and aliquoted into 1 million 
cells per mL of medium for single cell imaging flow cytometry. MDDCs receiving NU9056 
or CID were pre-treated with it for two hours followed by addition of 10 uM 2’,7’ –
dichlorofluorescein diacetate (DCF-DA) (Sigma, St. Louis, MO). For positive control, 
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hydrogen peroxide (50µM H2O2) was added, and the untreated control cells received just 
media. ROS was measured through single-cell imaging flow cytometry, where post alcohol 
or H2O2 treatment, viability dye DAPI was added to the cells, and 10,000 live single cell 
images per sample were acquired using Amnis FlowSight. Data were analyzed using 
Ideas software. DCF-DA positive cells were gated on total alive single cell images. 
5.2.3 MHC Class II marker HLA-DR expression study through single-cell imaging 
flow cytometry Post differentiation, HLA-DR quantification using single cell imaging flow 
cytometry, was carried out at three different time points. On Day 0, before beginning 
chronic treatment, 1 x 106 MDDCs were stained with an anti-HLA-DR-FITC labeled 
antibody (eBioscience) and DAPI and 10,000 events were acquired using Amnis 
FlowSight. Data were analyzed using Ideas software. HLA-DR - FITC positive cells were 
gated on total alive (DAPI negative) single cell images. Similarly, single cell imaging flow 
cytometry was carried out for MDDCs treated or untreated with EtOH on Day 3 and Day 
5 of chronic treatment. Additionally, on Day 5, MDDCs chronically treated with NU9056 or 
CID and their combination with EtOH were also studied for HLA-DR expression. 
5.2.4 cyclic AMP assay Cyclic AMP (cAMP) was measured using cAMP assay kit from 
R&D systems following the manufacturer’s protocol. In brief, post chronic treatment, cells 
were harvested divided into three groups for each treatment where one group received 
treatment with 100uM Forskolin (Tocris) for 15 minutes to induce cAMP, another group 
received 10mM Albuterol (Tocris) treatment for 15 minutes, while the other group did not 
receive any treatment. Post-treatment, cells were lysed, and cell lysates were assayed for 
levels of cAMP according to manufacturer’s instructions. 
5.2.5 Statistical analysis. Data are expressed as mean ± SEM. Experiments were 
performed at least three times or otherwise indicated in the figure legends. Statistical 
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analysis like student’s t-test and/or 1-way or 2-way ANOVA were done using either 
Microsoft Excel or GraphPad Prism software. For more than one treatment groups, post-
hoc analysis like Tukey’s multiple comparisons test was also carried out to test for 
significance. Values of the same have been expressed as F (DFn, DFd). P values were 
considered significant when they were ≤ 0.05.   
5.3 Results 
5.3.1 NU9056 and CID 16020046 were both able to reduce alcohol-induced MCP-2 
production. As the results from the arrays pointed towards MCP-2 as an inflammatory 
chemokine which may be positively regulated by H4K12ac, it was further studied to 
confirm if it was associated with GPR55 and if NU9056 and CID could reversed or inhibit 
the effects of EtOH. Post-treatment, MCP-2 expression was studied by single-cell imaging 
flow cytometry for untreated or control MDDCs and MDDCs treated with 0.2% EtOH, 
NU9056 50nM, CID 5uM or combination of NU9056 and CID with EtOH. Results as shown 
in figure 11, panel a, MDDCs treated with 0.2% EtOH have significantly increased 
percentage of cells expressing MCP-2 (76.0% ± 5.06, p=0.0005) compared to untreated 
control MDDCs (43.3% ± 3.94). Further, MDDCs treated with 0.2% EtOH + NU9056 have 
significantly decreased percentage of MCP-2 expressing cells (22.2% ± 3.45, p=0.0003) 
compared to 0.2% EtOH treated MDDCs. Similarly, MDDCs treated with 0.2% EtOH + 
CID have significantly decreased percentage of MCP-2 expressing cells (18.7% ± 0.57, 
p=0.0003) compared to 0.2% EtOH treated MDDCs. Panel b show representative overlay 
histogram of MCP-2 intensity where the rightmost histogram is that of 0.2% EtOH 
indicating its highest intensity for MCP-2 whereas leftward shift by 0.2% EtOH + NU9056 
and 0.2% EtOH + CID show decreased intensity for MCP-2. Panel c shows representative 
single cell images for each treatment.  
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5.3.2. Chronic alcohol treatments increase ROS production while NU9056 and CID 
16020046 were able to decrease alcohol-induced ROS production. Alcohol has been 
shown to cause ROS production and oxidative stress (Agudelo et al., 2011, Lu and 
Cederbaum, 2016, Wang et al., 2015, Liang et al., 2014a). Additionally, inflammation has 
also been commonly related to oxidative stress and ROS (Dandekar et al., 2015, Satapati 
et al., 2015). Having shown in our recent publication that H4K12ac may be an inflammation 
regulator (Parira et al., 2017a), the effect of NU9056 and CID was studied on ROS 
production by MDDCs to see if H4K12ac associated GPR55 expression had any effect on 
ROS production by MDDCs. Post treatments, ROS was assayed using DCF-DA and 
studied by single-cell imaging flow cytometry. As shown in figure 12, panel a, 0.2% EtOH 
(68.6% ± 8.5, p=0.001) significantly increases percentage of ROS producing cells 
compared to control MDDCs (45.5% ± 4.5). Additionally, 0.2% EtOH + NU9056 50nM 
(21.6% ± 3.31, p=0.0001) significantly reduces percentage of ROS producing cells 
compared to 0.2% EtOH treated MDDCs. Further, 0.2% EtOH + CID 5uM (38.2% ± 14.4, 
p=0.01) significantly reduces percentage of ROS producing cells compared to 0.2% EtOH 
treated MDDCs. Panel b shows representative single cell images. Panel c, d and e show 
representative overlay histograms for different treatments. 
5.3.3. NU9056 increases the percentage of cells expressing HLA-DR. To understand 
whether chronic alcohol treatment and H4K12ac associated GPR55 expression alters 
dendritic cell antigen presentation functionality, MHC Class II cell surface marker HLA-
DR, which has been shown to be expressed by mature dendritic cells that are presenting 
antigens (Radej et al., 2015, Shariat et al., 2014), was quantified at Day 0 (before starting 
chronic treatment), at Day 3 and Day 5 of chronic treatment with 0.2% EtOH. At Day 5, 
HLA-DR was also quantified in MDDCs treated with NU9056 and CID, in the presence or 
absence of EtOH. As shown in figure 13, panel a, there is no significant difference between 
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Day 0, 3 or 5 of chronic treatment between control and 0.2% EtOH treated MDDCs. Post 
chronic treatment, as shown in panel b, NU9056 (87.1% ± 5.5, p=0.05) significantly 
increases the percentage of cells expressing HLA-DR compared to control or untreated 
MDDCs (62.2% ± 9.2). All other treatments had no significant differences. 
5.3.4. Alcohol’s effect on H4K12ac associated GPR55 expression does not modulate 
cyclic AMP concentration in MDDCs. To further understand the cell signaling 
mechanism underlying alcohol-induced H4K12ac associated GPR55 increased 
expression, cyclic AMP levels were measured in chronically treated MDDCs under three 
different conditions. Post chronic treatment, MDDCs were divided into three groups, they 
were either treated with cyclic AMP inducer, Forskolin, or they were treated with beta 2 
adrenergic receptor inducer Albuterol or they were left untreated. Cyclic AMP was 
measured in cell lysates. As shown in the figure 14, even though no significant differences 
were found, overall, Albuterol failed to increase cyclic AMP in MDDCs treated with alcohol. 
Hence beta 2 adrenergic receptors do not play a role when it comes to alcohol modulation 
of the cyclic AMP in MDDCs. Forskolin, however, was able to increase overall levels of 
cyclic AMP in all treatments except GPR55 agonist 250 nM O1602 treated MDDCs. 
Concentration of O1602 was determined by XTT viability assay and assaying GPR55 
expression (Supplementary figure S2). Further, NU9056 and CID have a similar effect on 
cyclic AMP levels. These data revealed that even though alcohol showed alterations in 
cyclic AMP other downstream signaling molecules of GPCRs may be of more importance.  
5.4 Discussion 
Inflammation and oxidative stress are two important aspects of the 
pathophysiology of AUDs (Gonzalez-Reimers et al., 2014). Based on data suggesting 
H4K12ac may be positively regulating MCP-2, we measured MCP-2 levels in MDDCs 
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treated with NU9056, CID alone or in combination with 0.2 % EtOH. Interestingly, both 
NU9056 and CID in combination with 0.2% EtOH reduced MCP-2 levels in MDDCs 
compared to 0.2% EtOH alone. Hence, Both NU9056 and CID could serve as anti-
inflammatory drug targets given that they can reduce levels of inflammatory chemokine 
MCP-2 (Asano et al., 2015). However, we previously saw NU9056 also has a pro-
inflammatory effect where it was increasing levels of inflammatory cytokines and 
chemokines. This needs to be further addressed in the future and levels of these cytokines 
should be measured after treating MDDCs with CID to understand the role of GPR55 in 
their expression. To further study the role of H4K12ac as an oxidative stress regulator, 
ROS levels were measured in MDDCs post chronic treatment. Remarkably, both NU9056 
and CID were able to reduce ROS levels compared to 0.2% EtOH; therefore, indicating, 
firstly, H4K12ac may be an oxidative stress regulator, secondly, both NU9056 and CID 
may be potential therapeutic antioxidant targets. Previous studies have also shown 
therapeutic effects of NU9056 and CID. In a mice model of colitis or intestinal 
inflammation, CID was shown to reduce intestinal inflammation by decreasing 
macrophage migration and activation (Stancic et al., 2015). NU9056 was also found to 
have an anti-inflammatory activity where it was found to reduce cytosolic phospholipase 
A2 which leads to expression or pro-inflammatory factors like eicosanoids, in 
neuroblastoma cells under oxygen-glucose deprivation injury (Tan et al., 2016b). Based 
on these studies, our results show NU9056 and CID may be considered as therapeutic 
drug targets and developed as effective anti-inflammatory or anti-oxidants. 
Dendritic cells are one of the primary professional antigen presenting cells (APC’s) 
(Banchereau et al., 2000) and they are characterized by MHC class molecules on their 
surface which helps present antigens (Paul and Neefjes, 2013). HLA-DR is one such MHC 
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class II group molecule that is expressed by mature dendritic cells and help in antigen 
presentation (Buttari et al., 2008). Apart from being inflammation and oxidative stress 
regulator, to asses H4K12ac’s role in modulating DC functionality, HLA-DR expression 
was measured in MDDCs chronically treated with 0.2% EtOH along with MDDCs treated 
only with NU9056 or CID or 0.2% EtOH + NU9056 and 0.2% EtOH + CID. Results showed 
the only treatment which had a significant effect was NU9056, significantly increasing 
HLA-DR compared to untreated MDDCs. This means, blocking H4K12ac alters MDDC 
function.  Previous studies have shown that both acute and chronic alcohol prevents 
human MDDCs from maturing and differentiating (Buttari et al., 2008). In this study Buttari 
et al., demonstrated that MDDCs from alcoholics showed decreased CD86 expression 
and increased HLA-DR expression compared to MDDCs from non-drinkers. Other 
treatments, however, did not affect HLA-DR expression. Even though previous studies 
show alcohol modulates HLA-DR, our results of increased maturation or differentiation 
when H4K12ac is blocked may signify the role of H4K12ac as a modulator of genes 
responsible for antigen presentation. However, further studies, especially co-localization 
studies to understand antigen presentation is required to grasp this mechanism in-depth. 
Finally, to assess the role of H4K12ac in GPR55 functionality, GPCR downstream 
signaling molecule, cyclic AMP, (Hill et al., 2010) was measured in MDDCs under chronic 
alcohol treatment. Apart from measuring baseline levels, post chronic treatment, MDDCs 
were treated with two different compounds, Forskolin and Albuterol. Interestingly there 
were no significant differences between any treatments in either group. Albuterol, a beta 
2 adrenergic receptor agonist (Luchowska et al., 2009) was not able to increase cyclic 
AMP levels above baseline, indicating they are not responsible for cyclic AMP being 
detected in the cells. Forskolin, apart from being able to increase cyclic AMP levels overall 
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compared to baseline, showed opposite effects when compared between GPR55 agonist 
O1602 and GPR55 antagonist CID. In addition, NU9056 and CID as expected had the 
same effect on cyclic AMP compared to control. According to previous studies, GPR55 
agonists like lysophosphatidylcholine (LPC) and abnormal Cannabidiol (abn-CBD) did not 
show any significant modulation in the cyclic AMP (Ruz-Maldonado et al., 2018, Drzazga, 
2018 #418); however, CB2 agonists have been shown to inhibit cyclic AMP (Herring et al., 
1998). Additionally, literature shows, GPR55 heterodimerizes with CB2 to modulate 
downstream cell signaling (Balenga et al., 2014), further, GPR55 ligands also promote 
receptor coupling to multiple cell signaling pathways (Henstridge et al., 2010). Based on 
these studies, it may be more complex to understand the mechanisms behind H4K12ac-
GPR55 signaling and it may be helpful to study other GPCR cell signaling components 
like calcium levels and NFkB levels (El Zein et al., 2007).  
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Figure 11: NU9056 and CID 16020046 were both able to reduce alcohol-induced 
MCP-2 production.  
 
Post chronic treatment, MCP-2 expression was studied by single-cell imaging flow 
cytometry for untreated or control MDDCs and MDDCs treated with 0.2% EtOH, NU9056 
50nM, CID 5uM or combination of NU9056 and CID with EtOH. MDDCs were labelled with 
eFluor 450 to acquire live cell images only followed by FITC labelled antibody against 
MCP-2. Panel a shows percentage of FITC positive or MCP-2 expressing single cells. 
MDDCs treated with 0.2% EtOH have significantly increased percentage of cells 
expressing MCP-2 (76.0% ± 5.06, p=0.0005) compared to untreated control MDDCs 
(43.3% ± 3.94). Further, MDDCs treated with 0.2% EtOH + NU9056 have significantly 
decreased percentage of MCP-2 expressing cells (22.2% ± 3.45, p=0.0003) compared to 
0.2% EtOH treated MDDCs. Similarly, MDDCs treated with 0.2% EtOH + CID have 
significantly decreased percentage of MCP-2 expressing cells (18.7% ± 0.57, p=0.0003) 
compared to 0.2% EtOH treated MDDCs. 1-way ANOVA showed significant difference 
between treatments F(5,36)=37.08, p<0.0001. The experiment was carried out at least 
thrice. Data is represented as Mean ± SEM. Statistical differences were calculated using 
student’s t-test when each treated samples were individually compared to untreated 
control and 1-way ANOVA followed by Tukey’s multiple comparisons test to test for 
significance between treatments, significant differences are indicated with * for p≤0.05. 
Panel b show representative overlay histogram of MCP-2 intensity. Panel c shows 
representative single cell images for each treatment.  
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Figure 12: Chronic alcohol treatments increase ROS production while NU9056 and 
CID 16020046 were able to decrease alcohol-induced ROS production.  
 
Post chronic treatment, MDDCs were re-treated with NU9056 or CID followed by 
incubation with 10uM DCF-DA. Post incubation with DCF-DA, for positive control, 
hydrogen peroxide (50µM H
2
O
2
) was added, MDDCs receiving EtOH were re-treated with 
0.2% EtOH and the untreated control cells received just media. ROS was measured 
through single-cell imaging flow cytometry after 15 minutes, where post alcohol or H
2
O
2
 
treatment, viability dye DAPI was added to the cells, and 10,000 live single cell images 
per sample were acquired using Amnis FlowSight. Data were analyzed using Ideas 
software. DCF-DA positive cells were gated on total alive single cell images. Panel a, 0.2% 
EtOH (68.6% ± 8.5, p=0.001) significantly increases percentage of ROS producing cells 
compared to control MDDCs (45.5% ± 4.5). Additionally, 0.2% EtOH + NU9056 50nM 
(21.6% ± 3.31, p=0.0001) significantly reduces percentage of ROS producing cells 
compared to 0.2% EtOH treated MDDCs. Further, 0.2% EtOH + CID 5uM (38.2% ± 14.4, 
p=0.01) significantly reduces percentage of ROS producing cells compared to 0.2% EtOH 
treated MDDCs. 1-way ANOVA showed a significant difference between treatments 
(F(5,54)=8.916, p<0.0001). The experiment was carried out at least thrice in duplicates. 
Data is represented as Mean ± SEM. Statistical differences were calculated using 
student’s t-test when each treated samples were individually compared to untreated 
control and 1-way ANOVA followed by Tukey’s multiple comparisons test to test for 
significance between treatments, significant differences are indicated with * for p≤0.05. 
Panel b shows representative single cell images. Panel c, d and e show representative 
overlay histograms for different treatments. 
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Figure 13: NU9056 increases the percentage of cells expressing HLA-DR.  
 
Post differentiation, HLA-DR expression was quantified by single cell imaging flow 
cytometry on Day 0 that is before beginning chronic alcohol treatment, on Day 3 after 
beginning treatment and on Day 5 after finishing chronic treatment. On day 5, MDDCs 
chronically treated with NU9056 or CID or in combination with EtOH 0.2% was also 
analyzed for HLA-DR expression. MDDCs were surface labelled with anti-HLA-DR FITC 
labelled antibody followed by addition of DAPI to gate on live single cell images. As shown 
in panel a, there is no significant difference between Day 0, 3 or 5 of chronic treatment 
between control and 0.2% EtOH treated MDDCs. Post chronic treatment, as shown in 
panel b, NU9056 (87.1% ± 5.5, p=0.05) significantly increases the percentage of cells 
expressing HLA-DR compared to control or untreated MDDCs (62.2% ± 9.2). All other 
treatments had no significant differences. The experiment was carried out at least thrice. 
One-way ANOVA was carried out to check for interaction and did not show any 
significance. Data is represented as Mean ± SEM. Statistical differences were calculated 
using student’s t-test when individually compared to untreated control and 1-way ANOVA 
followed by Tukey’s multiple comparisons test to test for significance between treatments, 
significant differences are indicated with * for p≤0.05. Panel c shows representative single 
cell images. Panel d and e show representative overlay histogram of HLA-DR intensity 
corresponding to panel a and b respectively.  
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Figure 14: Alcohol’s effect on H4K12ac associated GPR55 expression does not modulate cyclic AMP concentration in 
MDDCs.  
Post chronic treatment, MDDCs were harvested and divided into three groups, one receiving Forskolin, one receiving albuterol and 
one not receiving any further treatment. Cell lysates from these MDDCs were analyzed for cyclic AMP levels. No significant 
differences were found. Data is represented as Mean ± SEM from at least two experiments. Statistical differences were calculated 
using student’s t-test when individually compared to untreated control and 1-way ANOVA followed by Tukey’s multiple comparisons 
test to test for significance between treatments.  
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Supplementary figure S2: XTT and GPR55 expression measurement assay point towards O1602 250nM as optimum 
concentration for chronic treatments. Panel a: XTT assay shows 5uM O1602 (37% ± 3, p<0.0001) and 10uM O1602 (34% ± 1, 
p<0.0001) causes significant cell death compared to untreated MDDCs. Other treatments do not have any significant difference. 
Experiment was carried out at least twice. Data is represented as Mean ± SEM. Statistical differences were calculated using 
student’s t-test when individually compared to untreated control and significant differences are indicated with * for p≤0.05. GPR55 
expression measurement by single cell imaging flow cytometry showed 250 nM O1602 to cause maximum increase in expression 
of GPR55 compared to untreated control. Panel b shows percentage of GPR55 positive single cells in MDDCs treated with O1602, 
concentration ranging from 25nM to 1uM. Panel c shows mean intensity of GPR55 representative of one experiment.  
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CHAPTER 6: Pitfalls and Alternative Strategies as future directions for this project 
This project overall was successful in elucidating the changes in epigenetic 
landscape particularly H3 and H4 quantity and H3 and H4 post-translational modifications 
using an in vitro model of chronic alcohol exposure of MDDCs. It was also able to show a 
correlational effect between H4K12ac and cannabinoid receptor GPR55 expression. 
Finally, it was also able to demonstrate a partial anti-inflammatory effect of NU9056 and 
CID suggesting H4K12ac be an inflammation regulator. It was also able to demonstrate 
the partial anti-oxidative property of NU9056 and CID suggesting H4K12ac to be an 
oxidative stress regulator in addition to an inflammation regulator.  
There were, however, some pitfalls that the project saw that could be overcome by 
utilizing alternate strategies. Some of these pitfalls have been discussed below.  
a. In the study to understand the purity of dendritic cell population and the effect on 
the same due to chronic culture with alcohol, about 10% of cell population was 
CD11c and CD14 double negative cells, about 10% was purely monocytic or CD14 
positive cells. These two groups which in total about 20% of cell population consist 
of cells other than dendritic cells may give rise to certain discrepancies in the 
studies. However, the other 80% of cell population is CD11c positive; hence, 
dendritic cells in either early or late stages of differentiation. This may contribute 
towards some understanding based on results as purely homogenous cell 
populations may give slightly different results than what we have observed (Aldo 
et al., 2013). This may be overcome by sorting cell populations after monocyte 
differentiation and prior to alcohol treatments to only carry out experiments in 
homogeneous cell populations.  
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b. The second pitfall in the project lies in the utilization of NU9056 to block H4K12ac. 
Even though we showed for the first time the ability of NU9056 to bring alcohol-
induced H4K12ac down to basal levels, it was not the most specific method to 
obtain the result. We observe this in the inflammatory cytokine arrays, where we 
saw a further increase in several cytokines and chemokines that were upregulated 
by alcohol apart from the decrease we saw in the alcohol-induced MCP-2. This 
may have happened due to several reasons including drug-drug interactions with 
alcohol, lack of specificity of NU9056 for TIP60 and finally the selected non-toxic 
concentration of NU9056 may not be enough to block TIP60 completely. As an 
alternative strategy, more specific siRNA or crispr-cas9 based silencing or 
knockdown of TIP60 gene may have a more pronounced effect on H4K12ac 
helping us better understand its functionality. We have recently published siRNA-
based silencing of TIP60 (Castillo-Chabeco et al., 2018); however, these 
experiments were performed in cells treated acutely with alcohol. Therefore, we 
need to carry out those experiments after exposure to different concentrations of 
alcohol and kinetic studies.  
c. The final pitfall lies in the question of whether alcohol itself or its metabolites have 
a role to play in the epigenetic effects as seen under chronic alcohol effects. To 
explore this question, we carried out an experiment where we pretreated MDDCs 
with alcohol dehydrogenase enzyme inhibitor 4 Methylpyrazole or 4-MP followed 
by chronic alcohol treatment. Post-treatment, we measured H4K12ac in MDDCs 
treated with 4-MP, 0.2% EtOH or both using single cell imaging flow cytometry. 
Results as shown in Supplementary figure S3, as expected 0.2% EtOH (85.67% ± 
5.7, p=0.0078) upregulated percentage of H4K12ac positive cells compared to 
untreated MDDCs (64.1% ± 1.8). 4-MP by itself does not affect the percentage of 
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H4K12ac positive cells compared to control; however, in combination with 0.2% 
EtOH (70% ± 3.6), it reduced the percentage of H4K12ac positive cells compared 
to 0.2% EtOH. These data indicate alcohol metabolites may have a role to play 
towards the epigenetic effects that we see after alcohol exposure. However, this 
may also be a result of toxicity caused by 4-MP. Previous literature show that 4-
MP may cause toxicity in rats and mice after chronic alcohol consumption 
(Magnusson et al., 1972, Kager and Ericsson, 1974). Even in recent reports, 4-MP 
has been shown to cause increased DNA adduct formations and oxidative stress 
(Sachse et al., 2016). Hence the effects of 4-MP that we see may stem from 
toxicity. To further confirm this as a future direction to this aspect, viability and 
toxicity assays using 4-MP and other alcohol metabolites including assays for 
apoptosis and necrosis to rule out toxicity as a confounding factor must be carried 
out.  
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Supplementary Figure S3: Role of alcohol dehydrogenase inhibitor in alcohol 
induced H4k12ac.  
MDDCs were pretreated with alcohol dehydrogenase enzyme inhibitor 4 Methylpyrazole 
or 4-MP followed by chronic alcohol treatment. Post-treatment, H4K12ac was measured 
in MDDCs treated with 4-MP, 0.2% EtOH or both using single cell imaging flow cytometry. 
As shown in the upper panel, 0.2% EtOH (85.67% ± 5.7, p=0.0078) upregulated 
percentage of H4K12ac positive cells compared to untreated MDDCs (64.1% ± 1.8). 4-
MP by itself does not affect the percentage of H4K12ac positive cells compared to control, 
however, in combination with 0.2% EtOH (70% ± 3.6), it reduced the percentage of 
H4K12ac positive cells compared to 0.2% EtOH but not significantly. 2-way ANOVA 
showed a significant column factor between treatments (F(4,20)=68.5, p<0.0001). The 
lower panel shows representative images. The experiment was carried out from four buffy 
coats. Data is represented as Mean ± SEM. Statistical differences were calculated using 
2-way ANOVA followed by Tukey’s multiple comparisons test to test for significance 
between treatments, significant differences are indicated with * for p≤0.05.  
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Chapter 7: CONCLUSION 
7.1 Conclusions 
A complex disorder like AUD with adverse outcomes ranging from that of injuries 
due to inebriation to liver cirrhosis and cancer needs all the support form researchers to 
overcome this formidable cause of death. The starting point of therapy lies in 
understanding the causes and mechanisms of a disorder or disease. Even after years of 
research on AUDs, the exact signaling mechanism that alcohol uses to cause its effects 
are unknown. Epigenetics, a study of all those factors that modulate gene expression may 
contain the answer to this question. The purpose of this project was to understand the 
underlying epigenetic mechanism to alcohol’s effect in human MDDCs. Results from this 
project were able to reveal that chronic alcohol treatments increase acetylation at H4K12 
in human MDDCs treated in vitro with alcohol. In order to understand how chronic alcohol 
exposure was able to increase acetylation at a histone residue we have to go back to the 
basics of mechanism of histone modifications and chromatin remodeling.  Chromatin is 
packaged in nucleosomes inside a cell nucleus for it to be accommodated inside the 
nucleus and regulate gene transcription and translation (Carone et al., 2014). 
Nucelosomes is a very effective way to regulate transcription as it either includes or 
occludes promoters from being exposed to transcription factors from binding to regulate 
gene expression (Lorch and Kornberg, 2015). This is where chromatin remodelers come 
into the picture (Clapier and Cairns, 2009). Remodelers or chromatin remodeling 
complexes use energy from ATP hydrolysis to remodel chromosome that includes moving, 
destabilizing, ejecting, or restructuring nucleosomes in the chromatin (Clapier and Cairns, 
2009). There are various families of remodelers, the SWI/SNF (switching 
defective/sucrose nonfermenting) family remodelers, ISWI (imitation switch) family 
remodelers, CHD (chromodomain, helicase, DNA binding) family remodelers and INO80 
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(inositol requiring 80) family remodelers as reviewed by Clapier et al. (Clapier and Cairns, 
2009). Further, histone modification enzymes like the HDACs, HATs and KMTs can act 
on nucleosomes to bring about post-translational modifications (Gong and Miller, 2013). 
Hence in order for a substance to modulate epigenetic modifications, it may be directly 
affecting the remodelers or the histone modification enzymes or a combination of both. 
Not much literature exists in the effect of alcohol on chromatin remodelers but recently a 
group of researchers found that BAF (BRG1/BRM-Associated Factor) part of the SWI/SNF 
group of remodeler showed ethanol sensitivity in neural progenitor stem cells (Burrowes 
et al., 2017). Another article studied alcohol effects in Caenorhabditis elegans and found 
SWI/SNF chromatin remodeling regulates alcohol response behaviors in the same 
(Mathies et al., 2015). However, more studies need to be carried out to see the effects of 
alcohol on chromatin remodelers to further understand the mechanism of alcohol’s effect 
on specific histone modifications. A lot of studies do exist on alcohol’s effect on histone 
modifying enzymes as discussed previously, which may be another method by which it is 
bringing about its epigenetic effects. 
Chronic alcohol treatments also modulate functionality of human MDDCs by 
upregulating GPR55 gene and protein, modulating inflammation via cytokine and 
chemokine secretion, oxidative stress via ROS production, and cell surface markers. All 
of these processes get modulated when H4K12ac is inhibited. To understand how 
H4K12ac can modulate such functions in MDDCs we have to take a closer look at the 
basic function of a histone acetylation. Histone acetylation in general is known to open up 
chromatin and make it available to transcription based on the negative charge of the 
histone acetyl groups (Gräff and Tsai, 2013). Acetylated lysines have been shown to be 
recognized by bromodomain containing proteins (Marmorstein and Zhou, 2014). Hence, 
when we call H4K12ac as an inflammation and oxidative stress regulator, what it might 
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mean is that certain bromodomain containing protein like bromodomain-PHD finger 
protein 1 (BRPF1) subunit of the monocytic leukemia zinc (MOZ) histone acetyltransferase 
(HAT) complex may bind to H4K12ac (Lubula et al., 2014) and lead to availability or 
promoters of genes responsible for inflammation, oxidative stress or even cell surface 
receptor expression. Once promoters are available, transcription factors along with RNA 
polymerase II can bind to promoters which leads to gene expression (Stasevich et al., 
2014). Certain groups of transcription factors are important players in inflammation like 
HIF (hypoxia-inducible factor) (Palazon et al., 2014), Egr2 and Egr 3 in B and T cells (Li 
et al., 2012), MEF2c, NFκB and KLF2 (Xu et al., 2015). The study of these transcription 
factors, may help further understanding the role of alcohol induced H4k12ac in regulating 
inflammation and oxidative stress. In conclusion, this project touches the surface of 
alcohol induced epigenetic modifications with emphasis in a small subset of cells and 
specific histone modifications revealed to be significantly upregulated after alcohol 
treatment in vitro. Therefore, further studies are necessary to understand this mechanism 
in-depth and to translate our findings using cells or biological samples from alcohol users.  
7.2 Future Directions 
Future directions for this project has some open ended questions for further research 
such as,  
- What is the histone acetylation state of H4K12 at the promoter region of 
GPR55? 
-  What is the histone acetylation state (H3 and H4 acetylation) at gene and 
promoter regions of CB1, CB2 and GPR55? 
- What downstream signaling molecules does this alcohol employ to bring 
about inflammatory and oxidative stress effects? 
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- Finally, will more specific blocking of H4K12ac and GPR55 help understand 
the significance of this pathway towards finding effective therapeutic 
treatment for AUDs?  
- Since all experiments were carried out in vitro after treatment of commercially 
available cells, as a future direction these findings should be translated into 
ex-vivo experiments from alcohol users at different stages of AUDs. 
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CHAPTER 8: SIGNIFICANCE 
The significance of this study lies in elucidating, for the first time, a novel epigenetic 
alteration observed in human MDDCs under the effect of chronic alcohol exposure. 
H4K12ac may have a significant role as an epigenetic biomarker and in the future may be 
developed for diagnostic purposes. Further, this study also elucidates, for the first time, 
an association between H4K12ac and cannabinoid receptor GPR55 expression under 
chronic alcohol exposure. This possible mechanism of alcohol action opens up several 
opportunities to understand the same in-depth. Additionally, this project also sheds light 
on two different possible therapeutic drug targets, NU9056 and CID, both of which 
compounds were able to show partial anti-inflammatory and anti-oxidative effects in 
alcohol treated MDDCs. However, further pharmacology based experiments both in vitro 
and in vivo are necessary to draw conclusions about their effectiveness as therapeutic 
drugs. In conclusion, the project was able to achieve its major goal of identifying a novel 
epigenetic pathway underlying alcohol effects in human MDDCs treated in vitro with 
chronic alcohol levels.  
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